AACP. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. AACAP.
Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37(Suppl 10):27S–45S. [
PubMed: 9785727]
Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review.
Journal of Consulting and Clinical Psychology. 1997;65:44–52. [
PubMed: 9103733]
Abramowitz JS. Treatment of obsessive-compulsive disorder in patients who have comorbid major depression.
Journal of Clinical Psychology. 2004;60:1133–1141. [
PubMed: 15389622]
Abramowitz JS, Schwartz SA, Moore KM, et al. Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature.
Journal of Anxiety Disorders. 2003;17:461–478. [
PubMed: 12826092]
Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 2002;22:309–317. [
PubMed: 12006902]
Albano AM, DiBartolo PM. Cognitive-behavioral treatment of obsessive-compulsive disorder and social phobia in children and adolescents, Innovations in Clinical Practice. Vande Creek L, editor. Vol. 15. Sarasota, Florida: Professional Resource Exchange Inc.; 1997. pp. 41–58.
Albert U, Aguglia E, Maina G, et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
Journal of Clinical Psychiatry. 2002;63:1004–1009. [
PubMed: 12444814]
Albert U, Maina G, Forner F, et al. DSM-IV obsessive-compulsive personality disorder: Prevalence in patients with anxiety disorders and in healthy comparison subjects.
Comprehensive Psychiatry. 2004;45:325–332. [
PubMed: 15332194]
Albertini RS, Phillips KA. Thirty-three cases of body dysmorphic disorder in children and adolescents.
Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:453–459. [
PubMed: 10199118]
Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
American Journal of Psychiatry. 2001;158:1143–1145. [
PubMed: 11431238]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: APA; 1980. DSM-III.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA; 1994. DSM-IV.
Amin MM, Ban TA, Pecknold JC, et al. Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders.
Journal of International Medical Research. 1977;5:33–37. [
PubMed: 340305]
Amir N, Freshman M, Foa EB. Family distress and involvement in relatives of obsessive-compulsive disorder patients.
Journal of Anxiety Disorders. 2000;14:209–217. [
PubMed: 10868980]
Ananth J, Pecknold JC, van den Steen N, et al. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis.
Progress in Neuro-Psychopharmacology. 1981;5:257–262. [
PubMed: 7022517]
Anderson D, Ahmed A. Treatment of patients with intractable obsessive-compulsive disorder with anterior capsular stimulation: case report.
Journal of Neurosurgery. 2003;98:1104–1108. [
PubMed: 12744372]
Ansseau M, Legros JJ, Mormont C, et al. Intranasal oxytocin in obsessive-compulsive disorder.
Psychoneuroendocrinology. 1987;12:231–236. [
PubMed: 3615752]
Ansseau M, Bejerot S, Blauwblomme JF, et al.
A double-blind study to compare the maintenance of efficacy and relapse rates in patients with obsessive-compulsive disorder who responded to paroxetine, clomipramine or placebo in the short-term study 136. [April 2004].
http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp [Study No.: MY-1056/BRL-029060/1/CPMS-241 (PAR 241)]
Antonelli F, de Gregorio M, Dionisio A. Trazodone in the treatment of psychoneuroses: a double-blind study.
Current Therapeutic Research, Clinical and Experimental. 1973;15:799–804. [
PubMed: 4201978]
Antony MM, Roth D, Swinson RP, et al. Illness intrusiveness in individuals with panic disorder, obsessive-compulsive disorder, or social phobia.
Journal of Nervous and Mental Disease. 1998;186:311–315. [
PubMed: 9612449]
Aouizerate B, Pujol H, Grabot D, et al. Body dysmorphic disorder in a sample of cosmetic surgery applicants.
European Psychiatry. 2003;18:365–368. [
PubMed: 14643566]
Apter A, Bernhout E, Tyano S. Severe obsessive compulsive disorder in adolescence: a report of eight cases.
Journal of Adolescence. 1984;7:349–358. [
PubMed: 6526960]
Apter A, Horesh N, Gothelf D, et al. Depression and suicidal behavior in adolescent inpatients with obsessive compulsive disorder.
Journal of Affective Disorders. 2003;75:181–189. [
PubMed: 12798258]
Askin R, Turan M, Cilli AS, et al. Clomipramine versus sertraline in the treatment of obsessive compulsive disorder. Klinik Psikofarmakoloji Buelteni. 1999;9:133–138.
Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.
International Clinical Psychopharmacology. 2002;17:115–119. [
PubMed: 11981352]
Baer L, Greist JH. An interactive computer-administered self-assessment and self-help program for behavior therapy.
J Clin Psychiatry. 1997;58 Suppl 12:23–28. [
PubMed: 9393393]
Baer L, Rauch SL, Ballantine HT Jr, et al. Cingulotomy for intractable obsessive-compulsive disorder: Prospective long-term follow-up of 18 patients.
Archives of General Psychiatry. 1995;52:384–392. [
PubMed: 7726719]
Bakken K, Landheim AS, Vaglum P. Primary and secondary substance misusers: do they differ in substance-induced and substance-independent mental disorders?
Alcohol and Alcoholism. 2003;38:54–59. [
PubMed: 12554609]
Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex.
Lancet. 1985;1(8437):1106–1107. [
PubMed: 2860322]
Barr LC, Goodman WK, Anand A, et al. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
American Journal of Psychiatry. 1997;154:1293–1295. [
PubMed: 9286191]
Barrett P, Shortt A, Healy L. Do parent and child behaviours differentiate families whose children have obsessive-compulsive disorder from other clinic and non-clinic families?
Journal of Child Psychology and Psychiatry. 2002;43:597–607. [
PubMed: 12120856]
Barrett P, Healy L, March JS. Behavioral avoidance test for childhood obsessive-compulsive disorder: a home-based observation.
American Journal of Psychotherapy. 2003;57:80–100. [
PubMed: 12647571]
Barrett P, Healy-Farrell L, March JS. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:46–62. [
PubMed: 14691360]
Barth FD. Obsessional thinking as ‘paradoxical action’
Bulletin of the Menninger Clinic. 1990;54:499–511. [
PubMed: 2268756]
Bartlett JR, Bridges PK. The extended subcaudate tractotomy lesion, Neurosurgical Treatment in Psychiatry, Pain and Epilepsy. Sweet WH, Obrador S, Martin-Rodriguez JG, editors. Baltimore: University Park Press; 1977.
Beale MD, Kellner CH, Pritchett JT, et al. ECT for OCD.
J Clin Psychiatry. 1995;56(2):81–82. [
PubMed: 7852259]
Beasley CM Jr, Potvin JH, Masica DN, et al. Fluoxetine: no association with suicidality in obsessive-compulsive disorder.
Journal of Affective Disorders. 1992;24:1–10. [
PubMed: 1545040]
Becker D, North MM. The virtual reality therapy system: VRT-2002. Cyberpsychology and Behavior. 1998;1:401–403.
Bejerot S. Psychosurgery for obsessive-compulsive disorder: concerns remain.
Acta Psychiatrica Scandinavica. 2003;107:241–243. [
PubMed: 12662245]
Bejerot S, Bodlund O. Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder.
Acta Psychiatrica Scandinavica. 1998;98:423–424. [
PubMed: 9845182]
Benazon NR, Ager J, Rosenberg DR. Cognitive behavior therapy in treatment-naive children and adolescents with obsessive-compulsive disorder: an open trial.
Behaviour Research and Therapy. 2002;40:529–539. [
PubMed: 12038645]
Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
Journal of Clinical Psychopharmacology. 2002;22:148–154. [
PubMed: 11910259]
Berle D, Starcevic V. Thought-action fusion: review of the literature and future directions.
Clinical Psychology Review. 2005;25:263–284. [
PubMed: 15792850]
Berlin JA. Does blinding of readers affect the results of meta-analysis? University of Pennsylvania Meta-Analysis Blinding Study Group.
Lancet. 2001;350(9072):185–186. [
PubMed: 9250191]
Biederman J, Petty C, Faraone SV, et al. Moderating effects of major depression on patterns of comorbidity in patients with panic disorder.
Psychiatry Research. 2004;126:143–149. [
PubMed: 15123393]
Bisserbe JC, Lane RM, Flament MF. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder.
European Psychiatry. 1997;12:82–93. [
PubMed: 19698511]
Black A. The natural history of obsessional neurosis, Obsessional States. Beech HR, editor. London: Methuen; 1974. pp. 19–54.
Black D, Noyes R. Obsessive-compulsive disorder and axis II. International Review of Psychiatry. 1997;9:111–118.
Black DW, Gaffney G, Schlosser S, et al. The impact of obsessive-compulsive disorder on the family: preliminary findings.
Journal of Nervous and Mental Disease. 1998;186:440–442. [
PubMed: 9680047]
Black DW, Gaffney GR, Schlosser S, et al. Children of parents with obsessive-compulsive disorder: a 2-year follow-up study.
Acta Psychiatrica Scandinavica. 2003;107:305–313. [
PubMed: 12662254]
Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings.
International Clinical Psychopharmacology. 1996;11:37–44. [
PubMed: 8732312]
Bloch S, Glue P. Psychotherapy and dysmorphophobia: a case report.
British Journal of Psychiatry. 1988;152:271–274. [
PubMed: 3167347]
Bobes J, Gonzalez MP, Bascaran MT, et al. Quality of life and disability in patients with obsessive-compulsive disorder.
European Psychiatry. 2001;16:239–245. [
PubMed: 11418275]
Boehm T. Sara in her fourth analytic year.
International Journal of PsychoAnalysis. 2002;83:1003–1008. [
PubMed: 12427261]
Boersma K, Den Hengst S, Dekker J, et al. Exposure and response prevention in the natural environment: a comparison with obsessive-compulsive patients.
Behaviour Research and Therapy. 1976;14:19–24. [
PubMed: 938416]
Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Psychiatry Research. 2000;96:91–98. [
PubMed: 11063782]
Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen.
European Neuropsychopharmacology. 2002;12:181–186. [
PubMed: 12007668]
Bohne A, Wilhelm S, Keuthen NJ. Prevalence of body dysmorphic disorder in a German college student sample.
Psychiatry Research. 2002;109:101–104. [
PubMed: 11850057]
Bolton D, Turner T. Obsessive-compulsive neurosis with conduct disorder in adolescence: a report of two cases.
Journal of Child Psychology and Psychiatry and Allied Disciplines. 1984;25:133–139. [
PubMed: 6693520]
Bolton D, Collins S, Steinberg D. The treatment of obsessive-compulsive disorder in adolescence: a report of fifteen cases.
British Journal of Psychiatry. 1983;142:456–464. [
PubMed: 6871559]
Bolton D, Luckie M, Steinberg D. Obsessive-compulsive disorder treated in adolescence: 14 long-term case histories. Clinical Child Psychology and Psychiatry. 1996;1:409–430.
Bouvard M. A standardized cognitive-behavioural group treatment program for obsessive compulsive disorder: preliminary outcomes.
Encephale. 2002;28:439–446. [
PubMed: 12386546]
Braddock LE. Dysmorphophobia in adolescence: a case report.
British Journal of Psychiatry. 1982;140:199–201. [
PubMed: 7074306]
Brawman-Mintzer O, Lydiard RB, Phillips KA, et al. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study.
American Journal of Psychiatry. 1995;152:1665–1667. [
PubMed: 7485632]
Brown KW, McGoldrick T, Buchanan R. Body dysmorphic disorder: seven cases treated with eye movement desensitization and reprocessing. Behavioural and Cognitive Psychotherapy. 1997;25:203–207.
Burgy M. The narcissistic function in obsessive-compulsive neurosis.
American Journal of Psychotherapy. 2001;55:65–73. [
PubMed: 11291192]
Butters JW, Cash TF. Cognitive-behavioral treatment of women's body-image dissatisfaction.
Journal of Consulting and Clinical Psychology. 1987;55:889–897. [
PubMed: 2891736]
Byerly MJ, Goodman WK, Christensen R. High doses of sertraline for treatment-resistant obsessive-compulsive disorder.
American Journal of Psychiatry. 1996;153:1232–1233. [
PubMed: 8780435]
Calvocoressi L, Lewis B, Harris M, et al. Family accommodation in obsessive-compulsive disorder.
American Journal of Psychiatry. 1995;152:441–443. [
PubMed: 7864273]
Calvocoressi L, Mazure CM, Kasl SV, et al. Family accommodation of obsessive-compulsive symptoms: instrument development and assessment of family behavior.
Journal of Nervous and Mental Disease. 1999;187:636–642. [
PubMed: 10535658]
Campisi TA. PhD thesis. Hofstra University; Hempstead, New York: 1995. Exposure plus response prevention in the treatment of body dysmorphic disorder.
Carpenter DJ, Schaefer DM, Lawnnson S, et al.
A 38-week, two phase, multicentre study to investigate the safety and effectiveness of paroxetine (10–60) mg/day) in the treatment of children and adolescent outpatients with obsessive-compulsive disorder. [April 2004].
http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp [Study No.: BRL-029060/RSD-100W81/1/CPMS-453]
Carroll BJ. Response of major depression with psychosis and body dysmorphic disorder to ECT.
American Journal of Psychiatry. 1994;158:288–289. [
PubMed: 8123174]
Casas M, Alvarez E, Duro P, et al. Antiandrogenic treatment of obsessive-compulsive neurosis.
Acta Psychiatrica Scandinavica. 1986;73:221–222. [
PubMed: 2939692]
Casey DA, Davis MH. Obsessive-compulsive disorder responsive to electroconvulsive therapy in an elderly woman.
South African Medical Journal. 1994;87:862–864. [
PubMed: 8052907]
Cassano GB, Castrogiovanni P, Mauri M. A multicenter controlled trial in phobic-obsessive psychoneurosis: the effect of chlorimipramine and of its combinations with haloperidol and diazepam.
Progress in Neuro-Psychopharmacology. 1981;5:129–138. [
PubMed: 7022513]
Castle DJ, Molton M, Hoffman K, et al. Correlates of dysmorphic concern in people seeking cosmetic enhancement.
Australian and New Zealand Journal of Psychiatry. 2004;38:439–444. [
PMC free article: PMC1613725] [
PubMed: 15209836]
Cela JA. A classical case of a severe obsessive compulsive defense. Modern Psychoanalysis. 1995;20:271–277.
Chakrabarti S, Kulhara P, Verma SK. The pattern of burden in families of neurotic patients.
Social Psychiatry and Psychiatric Epidemiology. 1993;28:172–177. [
PubMed: 8235803]
Chambless DL, Steketee G. Expressed emotion and behavior therapy outcome: a prospective study with obsessive-compulsive and agoraphobic outpatients.
Journal of Consulting and Clinical Psychology. 1999;67:658–665. [
PubMed: 10535232]
Chambless DL, Bryan AD, Aiken LS, et al. Predicting expressed emotion: a study with families of obsessive-compulsive and agoraphobic outpatients.
Journal of Family Psychology. 2001;15:225–240. [
PubMed: 11458630]
Chatterji NN. Psychoanalysis of an artist with obsessional symptoms. Samiksa. 1963;17:173–197.
Chiocca EA, Matuza RL. Neurosurgical therapy of obsessive compulsive disorder, Obsessive-Compulsive Disorders: Theory and Management. Jenike MA, Baer L, Minichiello WE, editors. Chicago: Year Book Medical; 1990. pp. 283–294.
Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.
Int Clin Psychopharmacol. 1992 Oct;7 Suppl 2:37–41. [
PubMed: 1484177]
Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Psychopharmacology Bulletin. 1990;26:279–284. [
PubMed: 2274626]
Chowdhury U, Frampton I, Heyman I. Clinical characteristics of young people referred to an obsessive compulsive disorder clinic in the United Kingdom. Clinical Child Psychology and Psychiatry. 2004;9:395–401.
Christensen H, Hadzi-Pavlovic D, Andrews G, et al. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review.
Journal of Consulting and Clinical Psychology. 1987;55:701–711. [
PubMed: 3331632]
Christensen DD, Laitinen LV, Schmidt LJ, et al. Anterior capsulotomy for treatment of refractory obsessive-compulsive disorder: results in a young and an old patient.
Stereotactic and Functional Neurosurgery. 2002;79:234–244. [
PubMed: 12890982]
Chung MS, Huang SC, Tsai SJ, et al. Mania associated with electroconvulsive therapy in a patient with obsessive compulsive disorder. International Medical Journal. 2001;8:185–186.
Churchill JE. Hypnotherapy and conjoint family therapy: a viable treatment combination.
American Journal of Clinical Hypnosis. 1986;28:170–176. [
PubMed: 3946286]
Clark DA. Cognitive-Behavioral Therapy for OCD. New York, NY: Guilford Press; 2004.
Clark DA, Beck AT. Clark-Beck Obsessive Compulsive Inventory. San Antonio, TX: The Psychological Corporation; 2002.
Clark DA, Sugrim I, Bolton D. Primary obsessional slowness: a nursing treatment programme with a 13-year-old male adolescent.
Behaviour Research and Therapy. 1982;20:289–292. [
PubMed: 7092770]
Clarke DJ, Boer H, Whittington J, et al. Prader-Willi syndrome, compulsive and ritualistic behaviours: the first population-based survey.
British Journal of Psychiatry. 2002;180:358–362. [
PubMed: 11925360]
Clomipramine Collaborative Study Group (CCSG). Clomipramine in the treatment of patients with obsessive-compulsive disorder.
Archives of General Psychiatry. 1991;48:730–738. [
PubMed: 1883256]
Cochrane Collaboration. Review Manager (Rev Man) [427 for Windows]. Oxford, England: The Cochrane Collaboration; 2004.
Cordioli AV, Heldt E, Bochi DB, et al. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial.
Psychotherapy and Psychosomatics. 2003;72:211–216. [
PubMed: 12792126]
Coryell WH, Black DW, Kelly MW, et al. HPA axis disturbance in obsessive-compulsive disorder.
Psychiatry Research. 1989;30:243–251. [
PubMed: 2694203]
Cosyns P, Caemaert J, Haaijman W, et al. Functional stereotactic neurosurgery for psychiatric disorders: an experience in Belgium and The Netherlands.
Advances and Technical Standards in Neurosurgery. 1994;21:239–279. [
PubMed: 7872975]
Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder.
International Clinical Psychopharmacology. 1990;5:17–30. [
PubMed: 2110206]
Cottraux J, Messy P, Marks IM, et al. Predictive factors in the treatment of obsessive-compulsive disorders with fluvoxamine and/or behaviour therapy. Behavioural Psychotherapy. 1993;21:45–50.
Cottraux J, Note I, Yao SN, et al. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder.
Psychotherapy and Psychosomatics. 2001;70:288–297. [
PubMed: 11598428]
Cox BJ, Swinson RP, Morrison B, et al. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis.
Journal of Behavior Therapy and Experimental Psychiatry. 1993;24:149–153. [
PubMed: 8263222]
Crago H. The anxious boys' newsletter. Australian and New Zealand Journal of Family Therapy. 1995;16:29–37.
Crocq MA. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.
European Psychiatry. 2002;17:296–297. [
PubMed: 12381502]
Cromarty P, Marks I. Does rational role-play enhance the outcome of exposure therapy in dysmorphophobia? A case study.
British Journal of Psychiatry. 1995;167:399–402. [
PubMed: 7496652]
Cui YH. A double-blind trial of chlorimipramine and doxepin in obsessive-compulsive neurosis.
Chung-Hua Shen Ching Ching Shen Ko Tsa Chih. [Chinese Journal of Neurology and Psychiatry]. 1986;19:279–281. Chinese. [
PubMed: 3556094]
Cumming S, Hay P, Lee T, et al. Neuropsychological outcome from psychosurgery for obsessive-compulsive disorder.
Australian and New Zealand Journal of Psychiatry. 1995;29:293–298. [
PubMed: 7487794]
Dale RC, Heyman I. Post-streptococcal autoimmune psychiatric and movement disorders in children.
British Journal of Psychiatry. 2002;181:188–190. [
PubMed: 12204920]
Dalton P. Family treatment of an obsessive-compulsive child: a case report.
Family Process. 1983;22:99–108. [
PubMed: 6840265]
D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2003;27:619–623. [
PubMed: 12787848]
Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.
European Neuropsychopharmacology. 2000;10:165–169. [
PubMed: 10793318]
De Araujo LA, Ito LM, Marks IM, et al. Does imagined exposure to the consequences of not ritualising enhance live exposure for OCD? A controlled study. I. Main outcome.
British Journal of Psychiatry. 1995;167:65–70. [
PubMed: 7551612]
De Araujo LA, Ito LM, Marks IM. Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder.
British Journal of Psychiatry. 1996;169:747–752. [
PubMed: 8968633]
De Haan E, Hoogduin KA, Buitelaar JK, et al. Behavior therapy versus clomipramine for the treatment of obsessive-compulsive disorder in children and adolescents.
Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:1022–1029. [
PubMed: 9785713]
Den Boer JA, Westenberg HG. Oxytocin in obsessive compulsive disorder.
Peptides. 1992;13:1083–1085. [
PubMed: 1494489]
Den Boer JA, Westenberg HG, Kamerbeek WD, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine.
International Clinical Psychopharmacology. 1987;2:21–32. [
PubMed: 3117876]
Denys D, van der Wee N, van Megen HJ, et al. Double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
International Journal of Neuropsychopharmacology. 2002;5:S131–S132. [
PubMed: 14624187]
Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.
Journal of Clinical Psychiatry. 2002;63(8):700–703. [
PubMed: 12197450]
Denys D, van Megen H, Westenberg H. The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder.
International Clinical Psychopharmacology. 2002;17:109–114. [
PubMed: 11981351]
Denys D, van der Wee N, van Megen H, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 2003;23:568–575. [
PubMed: 14624187]
Denys D, de Geus F, van Megen H, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Journal of Clinical Psychiatry. 2004;65:1040–1048. [
PubMed: 15323587]
Department of Health. Mental Health NSF (and the NHS Plan) Workforce Planning, Education and Training-Underpinning Programme: Adult Mental Health Services – Final Report by the Workforce Action Team. London: Department of Health; 2001.
Department of Health. Organising and Delivering Psychological Therapies. London: Department of Health; 2004.
Deri S. Case presentation.
Psychoanalytic Review. 1990;77:535–554. [
PubMed: 1708151]
DerSimonian R, Laird N. Meta-analysis in Clinical Trials.
Controlled Clinical Trials. 1986;7:177–188. [
PubMed: 3802833]
Desmarais PA, Lavallee YJ. Severe obsessive-compulsive syndrome in a 10 year old: a 3 year follow-up.
Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie. 1988;33:405–408. [
PubMed: 3409156]
Detweiler MF, Albano AM. Covert symptoms of obsessive-compulsive disorder in children: a case study. Journal of Cognitive Psychotherapy. 2001;15:75–86.
DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatric Annals. 1989;19:97–101.
DeVeaugh-Geiss J, Katz R, Landau P, et al. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.
Psychopharmacology Bulletin. 1990;26:54–59. [
PubMed: 2196627]
DeVeaugh-Geiss J, Katz R, Landau P, et al. Clomipramine hydrochloride (Anafranil) in the treatment of obsessive-compulsive disorder: results from three multicentre trials, Understanding Obsessive-Compulsive Disorder (OCD). Jenike MA, Asberg M, editors. Toronto: Hogrefe and Huber Publishers; Bern: Hans Huber; 1991. pp. 46–51.
DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31:45–49. [
PubMed: 1537780]
De Waal MWM, Arnold IA, Eekhof JAH, et al. Prevalence, functional impairment and comorbidity with anxiety and depressive disorders.
British Journal of Psychiatry. 2004;184:479–476. [
PubMed: 15172939]
Diamond BI, Borison RL, Katz R, et al. Rebound withdrawal reactions due to clomipramine.
Psychopharmacology Bulletin. 1989;25:209–212. [
PubMed: 2690164]
Di Blasi Z, Harkness E, Ernst E, et al. Influence of context effects on health outcomes: a systematic review.
Lancet. 2001;357(9258):757–762. [
PubMed: 11253970]
Doherr L, Reynolds S, Wetherly J, et al. Young children's ability to engage in cognitive therapy tasks: associations with age and educational experience. Behavioural and Cognitive Psychotherapy. 2005;33:201–215.
Dormaar JMM. February man revisited.
American Journal of Clinical Hypnosis. 1987;30:28–35. [
PubMed: 3310597]
Do Rosario-Campos MC, Leckman JF, Curi M, et al. A family study of early-onset obsessive-compulsive disorder.
Am J Med Genet B Neuropsychiatr Genet. 2005;136B(1):92–97. [
PubMed: 15892140]
Dougherty DD, Baer L, Cosgrove GR, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder.
American Journal of Psychiatry. 2002;159:269–275. [
PubMed: 11823270]
Dreessen L, Hoekstra R, Arntz A. Personality disorders do not influence the results of cognitive and behavior therapy for obsessive compulsive disorder.
Journal of Anxiety Disorders. 1997;11:503–521. [
PubMed: 9407270]
Drummond MF, O'Brien B, Stoddart GI, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997.
Dubois AM. A double-blind study of two types of psychiatric treatments. Genitif. 1983;5:91–101. French.
Dufresne RG, Phillips KA, Vittorio CC, et al. A screening questionnaire for body dysmorphic disorder in a cosmetic dermatologic surgery practice.
Dermatologic Surgery. 2001;27:457–462. [
PubMed: 11359494]
DuPont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive compulsive disorder.
Medical Interface. 1995;8:102–109. [
PubMed: 10141765]
Eccles M, Mason J. How to develop cost-conscious guidelines.
Health Technology Assessment. 2001;5:1–69. [
PubMed: 11427188]
Eccles M, Freemantle N, Mason J. North of England evidence-based guideline development project: methods of developing guidelines for efficient drug use in primary care.
BMJ. 1998;316:1232–1235. [
PMC free article: PMC1112989] [
PubMed: 9553004]
Eddy MF, Walbroehl GS. Recognition and treatment of obsessive-compulsive disorder.
American Family Physician. 1998;57:1623–1624. [
PubMed: 9556649]
Einat H, Shaldubina A, Belmaker RH. Epi-inositol: a potential antidepressant. Drug Development Research. 2000;50:309–315.
El-Khatib HE, Dickey TO. Sertraline for body dysmorphic disorder.
Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34:1404–1405. [
PubMed: 8543506]
Emmelkamp PM, Beens H. Cognitive therapy with obsessive-compulsive disorder: a comparative evaluation.
Behaviour Research and Therapy. 1991;29:293–300. [
PubMed: 1679324]
Emmelkamp PMG, de Lange I. Spouse involvement in the treatment of obsessive-compulsive patients.
Behaviour Research and Therapy. 1983;21:341–346. [
PubMed: 6626105]
Emmelkamp PMG, Foa EB. Failures are a challenge, Failures in Behaviour Therapy. Foa EB, Emmelkamp PMG, editors. New York: Wiley; 1983. pp. 1–9.
Emmelkamp PMG, Giesselbach P. Treatment of obsessions: relevant vs. irrelevant exposure. Behavioural Psychotherapy. 1981;9:322–329.
Emmelkamp PMG, Kraanen J. Therapist-controlled exposure in vivo versus self-controlled exposure in vivo: a comparison with obsessive-compulsive patients.
Behaviour Research and Therapy. 1977;15:491–495. [
PubMed: 23751]
Emmelkamp PMG, van der Heyden H. Treatment of harming obsessions. Behavioural Analysis and Modification. 1980;4:28–35.
Emmelkamp PM, van der Heyden H, van Zanten BL, et al. Treatment of obsessive-compulsive patients: the contribution of self-instructional training to the effectiveness of exposure.
Behaviour Research and Therapy. 1980;18:61–66. [
PubMed: 7369989]
Emmelkamp PM, Visser S, Hoekstra RJ. Cognitive therapy vs exposure in vivo in the treatment of obsessive-compulsives. Cognitive Therapy and Research. 1988;12:103–114.
Emmelkamp PM, van Linden van den Heuvell C, Ruphan M, et al. Home-based treatment of obsessive-compulsive patients: intersession interval and therapist involvement.
Behaviour Research and Therapy. 1989;27:89–93. [
PubMed: 2563327]
Emmelkamp PMG, de Haan E, Hoogduin CAL. Marital adjustment and obsessive-compulsive disorder.
British Journal of Psychiatry. 1990;156:55–60. [
PubMed: 1967545]
Enright SJ. Group treatment for obsessive-compulsive disorder: an evaluation. Behavioral Psychotherapy. 1991;19:183–92.
Erickson MH. Psychotherapy achieved by a reversal of the neurotic processes in a case of ejaculatio precox.
American Journal of Clinical Hypnosis. 1973;15:217–222. [
PubMed: 4130930]
Eriksson T. Antiandrogenic treatment for obsessive-compulsive disorder.
Am J Psychiatry. 2000 Mar;157(3):483. [
PubMed: 10698847]
Erzegovesi S, Ronchi P, Smeraldi E. 5HT-2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Human Psychopharmacology. 1992;7:287–289.
Esman AH. Obsessive-compulsive disorder: current views. Psychoanalytic Inquiry. 2001;21:145–156.
Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.
Archives of General Psychiatry. 1998;55:918–924. [
PubMed: 9783563]
Fals-Stewart W, Angarano. K. Obsessive-compulsive disorder among patients entering substance abuse treatment: prevalence and accuracy of diagnosis.
Journal of Nervous and Mental Disease. 1994;182:715–719. [
PubMed: 7989917]
Fals-Stewart W, Marks AP, Schafer J. A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder.
Journal of Nervous and Mental Disease. 1993;181:189–193. [
PubMed: 8445378]
Faravelli C, Salvatori S, Galassi F, et al. Epidemiology of somatoform disorders: a community survey in Florence.
Social Psychiatry and Psychiatric Epidemiology. 1997;32:24–29. [
PubMed: 9029984]
Feldman JD, Noshirvani H, Chu C. Improvement in female patients with severe obsessions and/or compulsions treated with cyproterone acetate.
Acta Psychiatrica Scandinavica. 1988;78:254. [
PubMed: 2975912]
Fields L. An integrative brief treatment approach for obsessive-compulsive disorder. Journal of Psychotherapy Integration. 1998;8:161–172.
Fine S. Family therapy and a behavioral approach to childhood obsessive-compulsive neurosis.
Archives of General Psychiatry. 1973;28:695–697. [
PubMed: 4700683]
Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder.
International Journal of Neuropsychopharmacology. 2004;7:1–23. [
PubMed: 15450126]
Fineberg NA, Roberts A. Obsessive compulsive disorder: a twenty-first century perspective, Obsessive Compulsive Disorder: A Practical Guide. Fineberg NA, Marazziti D, Stein D, editors. London: Martin Dunitz; 2001. pp. 1–13.
Fineberg NA, O'Doherty C, Rajagopal S, et al. How common is obsessive compulsive disorder in a dermatology outpatient clinic?
Journal of Clinical Psychiatry. 2003;64:152–155. [
PubMed: 12633123]
Finell JS, McDougall J. A case presentation: the treatment of a man with a severe obsessional disorder. Current Issues in Psychoanalytic Practice. 1985;2:3–24.
Fingert Chused J. Obsessional manifestations in children.
Psychoanalytic Study of the Child. 1999;54:219–232. [
PubMed: 10748634]
First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders – Clinician Version (SCID-CV). Washington DC: American Psychiatric Press; 1997.
Fischer DJ, Himle JA, Hanna GL. Group behavioral therapy for adolescents with obsessive-compulsive disorder: preliminary outcomes. Research on Social Work Practice. 1998;8:629–636.
Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study.
Archives of General Psychiatry. 1985;42:977–983. [
PubMed: 3899048]
Flament MF, Whitaker A, Rapoport JL, et al. Obsessive compulsive disorder in adolescence: an epidemiological study.
Journal of the American Academy of Child and Adolescent Psychiatry. 1988;27:764–771. [
PubMed: 3264280]
Foa EB, Franklin ME. Psychotherapies for obsessive-compulsive disorder: a review, Obsessive-Compulsive Disorder. Maj M, Sartorius N, Okasha A, et al., editors. New York: John Wiley & Sons Ltd; 2000. pp. 93–146. (WPA series evidence and experience in psychiatry).
Foa EB, Goldstein AJ. Continuous exposure and complete response prevention in the treatment of obsessive-compulsive neurosis. Behavior Therapy. 1978;9:821–829.
Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder, Long-Term Treatments of Anxiety Disorders. Mavissakalian MR, Prien RF, editors. Washington, DC: American Psychiatric Association; 1996. pp. 285–309.
Foa EB, Steketee G, Milby JB. Differential effects of exposure and response prevention in obsessive-compulsive washers.
Journal of Consulting and Clinical Psychology. 1980;48:71–79. [
PubMed: 7365045]
Foa EB, Steketee GS, Grayson JB, et al. Deliberate exposure and blocking of obsessive-compulsive rituals: immediate and long-term effects. Behavior Therapy. 1984;15:450–472.
Foa EB, Steketee GS, Oazrow BJ. Behavior therapy with obsessive-compulsives: from theory to treatment, Obsessive-Compulsive Disorder: Psychological and Pharmacological Treatments. Mavissakeliam M, Turner SM, Michelson L, editors. New York: Plenum; 1985. pp. 49–120.
Foa EB, Kozak MJ, Goodman WK, et al. DSM-IV field trial: obsessive compulsive disorder.
Am J Psychiatry. 1995;152(1):90–6. [
PubMed: 7802127]
Foa EB, Kozak MJ, Michael J, et al. The validation of a new obsessive-compulsive disorder scale: the obsessive-compulsive inventory. Psychological Assessment. 1998;10:206–214.
Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?
Biological Psychiatry. 2002;52:987–997. [
PubMed: 12437939]
Foa EB, Huppert JD, Leiberg S, et al. The Obsessive-Compulsive Inventory: development and validation of a short version.
Psychological Assessment. 2002;14:485–496. [
PubMed: 12501574]
Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
American Journal of Psychiatry. 2005;162:151–161. [
PubMed: 15625214]
Fodstad H, Strandman E, Karlsson B, et al. Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy.
Acta Neurochirurgica. 1982;62:1–23. [
PubMed: 7048859]
Fontenelle LF, Mendlowicz MV, Marques C, et al. Trans-cultural aspects of obsessive-compulsive disorder: a description of a Brazilian sample and a systematic review of international clinical studies.
Journal of Psychiatric Research. 2004;38:403–411. [
PubMed: 15203292]
Francis G. Childhood obsessive-compulsive disorder: extinction of compulsive reassurance-seeking. Journal of Anxiety Disorders. 1988;2:361–366.
Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Can J Psychiatry. 2001;46(4):356–358. [
PubMed: 11387793]
Franklin ME, Kozak MJ, Cashman LA, et al. Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:412–419. [
PubMed: 9549962]
Franklin ME, Tolin DF, March JS, et al. Treatment of pediatric obsessive-compulsive disorder: a case example of intensive cognitive-behavioral therapy involving exposure and ritual prevention. Cognitive and Behavioral Practice. 2001;8:297–304.
Franklin ME, Rynn M, Foa EB, et al. Treatment of obsessive compulsive disorder, Cognitive Therapy With Children and Adolescents: A Casebook for Clinical Practice. Reinecke MA, Datilio FM, Freeman A, editors. New York & London: Guilford Press; 2003. pp. 162–188.
Frare P, Lebel A. The use of ‘thought-stopping’ in the treatment of obsessive-compulsive disorder in a 9-year-old girl.
Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie. 1996;41:367–370. [
PubMed: 8983816]
Frare F, Perugi G, Ruffolo G, et al. Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features.
European Psychiatry. 2004;19:292–298. [
PubMed: 15276662]
Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Journal of Clinical Psychiatry. 1994;55:301–305. [
PubMed: 8071291]
Freeman C, Crossley D, Eccleston D. Neurosurgery for Mental Disorder: Report from the Neurosurgery Working Group of the Royal College of Psychiatrists. London: Royal College of Psychiatrists; 2000. p. CR89.
Freeston MH. Cognitive-behavioural treatment of a 14-year-old teenager with obsessive-compulsive disorder. Behavioural and Cognitive Psychotherapy. 2001;29:71–84.
Freeston M, Rheaume J, Ladouceur R. Correcting faulty appraisals of obsessive thoughts.
Behaviour Research and Therapy. 1996;34:446. [
PubMed: 8687365]
Freeston MH, Ladouceur R, Gagnon F, et al. Cognitive-behavioral treatment of obsessive thoughts: a controlled study.
Journal of Consulting and Clinical Psychology. 1997;65:405–413. [
PubMed: 9170763]
Freud S. Notes Upon a Case of Obsessional Neurosis (Reprinted 1955) in The Standard Edition of the Complete Psychological Works of Sigmund Freud. Strachey J, , translator and editor. Vol. 10. London: Hogarth Press; 1909.
Friedmann CT, Silvers FM. A multimodality approach to inpatient treatment of obsessive-compulsive disorder.
American Journal of Psychotherapy. 1977;31:456–465. [
PubMed: 900317]
Fritzler BK, Hecker JE, Losee MC. Self-directed treatment with minimal therapist contact: preliminary findings for obsessive-compulsive disorder.
Behaviour Research and Therapy. 1997;35:627–631. [
PubMed: 9193126]
Frost R, Steketee G. Issues in the treatment of compulsive hoarding. Cognitive and Behavioral Practice. 1999;6:397–407.
Frost R, Steketee G. Cognitive Approaches to Obsessions and Compulsions: Theory, Assessment, and Treatment. Amsterdam, Netherlands: Pergamon/Elsevier Science Inc.; 2002.
Furth GM, Smith R, Kubler-Ross E. Amputee Identity Disorder: Information, Questions, Answers and Recommendations About Self-Demand Amputation. Bloomington: 1st Books Library; 2000.
Fux M, Levine J, Aviv A, et al. Inositol treatment of obsessive-compulsive disorder.
American Journal of Psychiatry. 1996;153:1219–1221. [
PubMed: 8780431]
Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study.
International Journal of Neuropsychopharmacology. 1999;2:193–195. [
PubMed: 11281989]
Gabbard GO. Psychoanalytically informed approaches to the treatment of obsessive-compulsive disorder. Psychoanalytic Inquiry. 2001;21:208–221.
Gabriels L, Cosyns P, Nuttin B, et al. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases.
Acta Psychiatrica Scandinavica. 2003;107:275–282. [
PubMed: 12662250]
Garvey MA, Perlmutter SJ, Allen AJ, et al. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections.
Biological Psychiatry. 1999;45:1564–1571. [
PubMed: 10376116]
Geffken GR, Pincus DB, Zelikovsky N. Obsessive compulsive disorder in children and adolescents: review of background, assessment, and treatment. Journal of Psychological Practice. 1999;5:15–31.
Geisler A, Schou M. Lithium for obsessive-compulsive neuroses: a double-blind therapeutic trial.
Nordisk Psykiatrisk Tidsskrift. 1969;23:493–495. Danish. [
PubMed: 4917378]
Geller D, Biederman J, Jones J, et al. Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? A review of the pediatric literature.
Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:420–427. [
PubMed: 9549963]
Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:773–779. [
PubMed: 11437015]
Geller DA, Biederman J, Stewart SE, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
Journal of Child and Adolescent Psychopharmacology. 2003;13(Suppl 1):S19–S29. [
PubMed: 12880497]
Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1387–1396. [
PubMed: 15502598]
George MS. New methods of brain stimulation are improving research and therapy in obsessive-compulsive disorder. CNS Spectrum. 2000;5(6 (Suppl 4)):12–17.
Geremia GM, Neziroglu F. Cognitive therapy in the treatment of body dysmorphic disorder. Clinical Psychology and Psychotherapy. 2001;8:243–241.
Goktepe EO, Young LB, Bridges PK. A further review of the results of stereotactic subcaudate tractotomy.
British Journal of Psychiatry. 1975;126:270–280. [
PubMed: 47773]
Gold-Steinberg S, Logan D. Integrating play therapy in the treatment of children with obsessive-compulsive disorder.
American Journal of Orthopsychiatry. 1999;69:495–503. [
PubMed: 10553460]
Gomez de Setien DI. Transactional analysis and combined system of therapy for the modification of conduct. Transactional Analysis Journal. 1982;12:267–269.
Gomez-Perez JC, Marks IM, Gutierrez-Fisac JL. Dysmorphophobia: clinical features and outcome with behavior therapy. European Psychiatry. 1994;9:229–235.
Gomibuchi T, Gomibuchi K, Akiyama T, et al. Obsession of hearing music: from the viewpoint of morita theory.
Psychiatry and Clinical Neurosciences. 2000;54:203–206. [
PubMed: 10803816]
Goodman R. Psychometric properties of the strengths and difficulties questionnaire.
Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:1337–1345. [
PubMed: 11699809]
Goodman RW. Applications of strategic therapy with children. Journal of Child and Adolescent Psychotherapy. 1988;5(1):11–14.
Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
Archives of General Psychiatry. 1989;46:36–44. [
PubMed: 2491940]
Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
Archives of General Psychiatry. 1990;47:577–585. [
PubMed: 2112374]
Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
International Clinical Psychopharmacology. 1996;11:21–29. [
PubMed: 8732310]
Gothelf D, Aharonovsky O, Horesh N, et al. Life events and personality factors in children and adolescents with obsessive-compulsive disorder and other anxiety disorders.
Comprehensive Psychiatry. 2004;45:192–198. [
PubMed: 15124149]
Gournay K, Veale D, Walburn J. Body dysmorphic disorder: pilot randomized controlled trial of treatment; implications for nurse therapy research and practice. Including commentary by Newell R and Latham M with author response. Clinical Effectiveness in Nursing. 1997;1:38–46.
Gournay K, Denford L, Parr AM, et al. British nurses in behavioural psychotherapy: a 25-year follow-up.
Journal of Advanced Nursing. 2000;32:343–351. [
PubMed: 10964181]
Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
American Journal of Psychiatry. 1993;150:819–821. [
PubMed: 8480832]
Grant JE. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.
Journal of Clinical Psychiatry. 2001;62:297–298. [
PubMed: 11379848]
Grant JE, Won Kim S, Eckert ED. Body dysmorphic disorder in patients with anorexia nervosa: prevalence, clinical features, and delusionality of body image.
International Journal of Eating Disorders. 2002;32:291–300. [
PubMed: 12210643]
Green D. A behavioural approach to the treatment of obsessional rituals: an adolescent case study.
Journal of Adolescence. 1980;3:297–306. [
PubMed: 7007456]
Greenberg BD, Rezai AR. Mechanisms and the current state of deep brain stimulation in neuropsychiatry.
CNS Spectrum. 2003;8:522–526. [
PubMed: 12894033]
Greenberg BD, George MS, Martin JD, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study.
American Journal of Psychiatry. 1997;154:867–869. [
PubMed: 9167520]
Greist JH, Jefferson JW, Rosenfeld R, et al. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
Journal of Clinical Psychiatry. 1990;51:292–297. [
PubMed: 2195006]
Greist JH, Jefferson JW, Kobak KA, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
International Clinical Psychopharmacology. 1995;10:57–65. [
PubMed: 7673657]
Greist JH, Marks IM, Baer L, et al. Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control.
Journal of Clinical Psychiatry. 2002;63:138–145. [
PubMed: 11874215]
Greist JH, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults.
CNS Spectrum. 2003;8(8 (Suppl 1)):7–16. [
PubMed: 14767394]
Haaga DA. Introduction to the special section on stepped care models in psychotherapy.
Journal of Consulting and Clinical Psychology. 2000;68:547–548. [
PubMed: 10965628]
Hackmann A, McLean C. A comparison of flooding and thought stopping in the treatment of obsessional neurosis.
Behaviour Research and Therapy. 1975;13:263–269. [
PubMed: 242308]
Hafner JR, Gilchrist P, Bowling J, et al. The treatment of obsessional neurosis in a family setting.
Australian and New Zealand Journal of Psychiatry. 1981;15:145–151. [
PubMed: 6945105]
Hafner RJ. Marital interaction in persisting obsessive-compulsive disorders.
Australian and New Zealand Journal of Psychiatry. 1982;16:171–178. [
PubMed: 6960888]
Hallam RS. Extinction of ruminations: a case study. Behavior Therapy. 1974;5:565–568.
Hand I. Obsessive-compulsive patients and their families, Handbook of Behavioral Family Therapy. Halloon M, editor. New York, NY: Guilford Press; 1988. pp. 231–256.
Hanna GL, Himle JA, Curtis GC, et al. A family study of obsessive-compulsive disorder with pediatric probands.
American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics. 2005;134:13–19. [
PubMed: 15635694]
Harbin HT. Cure by ordeal: treatment of an obsessive-compulsive neurotic. International Journal of Family Therapy. 1979;1:324–332.
Harris CV, Wiebe DJ. An analysis of response prevention and flooding procedures in the treatment of adolescent obsessive compulsive disorder.
Journal of Behavior Therapy and Experimental Psychiatry. 1992;23:107–115. [
PubMed: 1360985]
Harris DL, Carr AT. Prevalence of concern about physical appearance in the general population.
British Journal of Plastic Surgery. 2001;54:223–226. [
PubMed: 11254414]
Harvey MA, Green CL. Looking into a deaf child's future: a brief treatment approach.
American Annals for the Deaf. 1990;135:364–370. [
PubMed: 2091450]
Hay P, Sachdev P, Cumming S, et al. Treatment of obsessive-compulsive disorder by psychosurgery.
Acta Psychiatrica Scandinavica. 1993;87:197–207. [
PubMed: 8096667]
Hembree EA, Riggs DS, Kozak MJ, et al. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.
CNS Spectrum. 2003;8:363–371. [
PubMed: 12766692]
Hesso R, Thorell LH. Lithium treatment for obsessive-compulsive neuroses. A little clinical-therapeutic pilot study of the double-blind cross-over type.
Nordisk Psykiatrisk Tidsskrift. 1969;23:496–499. Swedish. [
PubMed: 4393979]
Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders.
American Journal of Psychiatry. 2001;158:1568–1578. [
PubMed: 11578982]
Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 1992;12:420–430. [
PubMed: 1474179]
Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.
Journal of Clinical Psychiatry. 2003;64:1025–1030. [
PubMed: 14628977]
Heyman I, Fombonne E, Simmons H, et al. Prevalence of obsessive compulsive disorder in the British nationwide survey of child mental health.
British Journal of Psychiatry. 2001;179:324–329. [
PubMed: 11581112]
Higgins JPT, Thompson SG. Qualifying heterogeneity in a meta-analysis.
Statistics in Medicine. 2002;21:1539–1558. [
PubMed: 12111919]
Himle JA, van Etten M, Fischer DJ. Group cognitive behavioral therapy for obsessive-compulsive disorder. Brief Treatment and Crisis Intervention. 2003;3:217–229.
Hiss H, Foa EB, Kozak MJ. Relapse prevention program for treatment of obsessive-compulsive disorder.
Journal of Consulting and Clinical Psychology. 1994;62:801–808. [
PubMed: 7962884]
Hodgkiss AD, Malizia AL, Bartlett JR, et al. Outcome after the psychosurgical operation of stereotactic subcaudate tractotomy, 1979–1991.
Journal of Neuropsychiatry and Clinical Neurosciences. 1995;7:230–234. [
PubMed: 7626968]
Hoehn-Saric R, Ninan P, Black DW, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
Archives of General Psychiatry. 2000;57:76–82. [
PubMed: 10632236]
Hohagen F, Winkelmann G, Rasche-Ruchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study.
British Journal of Psychiatry – Supplementum. 1998;173(Suppl 35):71–78. [
PubMed: 9829029]
Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs.
Br J Psychiatry Suppl. 1998;173(35):7–12. [
PubMed: 9829021]
Hollander E, Wong CM. Obsessive-compulsive spectrum disorders.
J Clin Psychiatry. 1995;56 Suppl 4:53–55. [
PubMed: 7713863]
Hollander E, Wong C. Psychosocial functions and economic costs of obsessive compulsive disorder. CNS Spectrum. 1998;3(5):48–58.
Hollander E, Liebowitz MR, Winchel R, et al. Treatment of body-dysmorphic disorder with serotonin reuptake blockers.
American Journal of Psychiatry. 1989;146:768–770. [
PubMed: 2658627]
Hollander E, Stein DJ, DeCaria CM, et al. A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
Biological Psychiatry. 1993;33:747–749. [
PubMed: 8353170]
Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
Archives of General Psychiatry. 1999;56:1033–1039. [
PubMed: 10565503]
Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
Journal of Clinical Psychiatry. 2003;64:640–647. [
PubMed: 12823077]
Hollander E, Baldini RN, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
International Journal of Neuropsychopharmacology. 2003;6:397–401. [
PubMed: 14604454]
Hollander E, Friedberg J, Wasserman S, et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder.
Journal of Clinical Psychiatry. 2003;64:546–550. [
PubMed: 12755657]
Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder.
World Journal of Biological Psychiatry. 2003;4:30–34. [
PubMed: 12582975]
Hollander E, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
Journal of Clinical Psychiatry. 2003;64:1113–1121. [
PubMed: 14628989]
Horowitz K, Gorfinkle K, Lewis O, et al. Body dysmorphic disorder in an adolescent girl.
Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1503–1509. [
PMC free article: PMC1613829] [
PubMed: 12447038]
Horwath E, Weissman MM. The epidemiology and cross-national presentation of obsessive-compulsive disorder.
Psychiatric Clinics of North America. 2000;23:493–507. [
PubMed: 10986723]
Hughes A, Fineberg N, Roberts A, et al. Group cognitive behaviour therapy in obsessive compulsive disorder (OCD): a controlled study.
2004 Unpublished trial. [
PubMed: 24930923]
Husain MM, Lewis SF, Thornton WL. Maintenance ECT for refractory obsessive-compulsive disorder.
American Journal of Psychiatry. 1993;150:1899–1900. [
PubMed: 8238655]
Insel TR, Alterman I, Murphy DL. Antiobsessional and antidepressant effects of clomipramine in the treatment of obsessive-compulsive disorder.
Psychopharmacology Bulletin. 1982;18:115–117. [
PubMed: 7156271]
Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline.
Archives of General Psychiatry. 1983;40:605–612. [
PubMed: 6342562]
Insel TR, Mueller EA, Alterman I, et al. Obsessive-compulsive disorder and serotonin: is there a connection?
Biological Psychiatry. 1985;20:1174–1188. [
PubMed: 2413912]
Ishigooka J, Mitsuhiro I, Makihiko S, et al. Demographic features of patients seeking cosmetic surgery.
Psychiatry and Clinical Neuroscience. 1998;52:283–287. [
PubMed: 9681579]
Issakidis C, Sanderson K, Corry J, et al. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
Psychological Medicine. 2004;34:19–35. [
PubMed: 14971624]
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary?
Controlled Clinical Trials. 1996;17:1–12. [
PubMed: 8721797]
Jenike MA. A case report of successful treatment of dysmorphophobia with tranylcypromine.
American Journal of Psychiatry. 1984;141:1463–1464. [
PubMed: 6149701]
Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
American Journal of Psychiatry. 1990;147:1209–1215. [
PubMed: 2143637]
Jenike MA, Baer L, Summergrad P, et al. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.
American Journal of Psychiatry. 1990;147:923–928. [
PubMed: 2192564]
Jenike MA, Baer L, Ballantine T, et al. Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients.
Archives of General Psychiatry. 1991;48:548–555. [
PubMed: 2039338]
Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder.
American Journal of Psychiatry. 1997;154:1261–1264. [
PubMed: 9286186]
Jianxun L, Hu X, Haiying D. Clinical controlled study of paroxetine and clomipramine in treatment of obsessive-compulsive disorder. Chinese Journal of Psychiatry. 1998;31:215–217. Chinese.
Johnson GM, Hallenbeck CE. A case of obsessional fears treated by brief hypno-imagery intervention.
American Journal of Clinical Hypnosis. 1985;27:232–236. [
PubMed: 4014056]
Jones MK, Menzies RG. Danger ideation reduction therapy (DIRT) for obsessive-compulsive washers. A controlled trial.
Behaviour Research and Therapy. 1998;36:959–970. [
PubMed: 9714946]
Jordan J, Joyce PR, Carter FA, et al. Anxiety and psychoactive substance use disorder comorbidity in anorexia nervosa or depression.
International Journal of Eating Disorders. 2003;34:211–219. [
PubMed: 12898557]
Juni S. From the analysis of an obsessive hummer: theoretical and clinical implications.
Psychoanalytic Review. 1987;74:63–81. [
PubMed: 3112830]
Kamijima K, Murasaki M, Asai M, et al. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
Psychiatry and Clinical Neuroscience. 2004;58:427–433. [
PubMed: 15298657]
Karabanow O. Double-blind controlled study in phobias and obsessions.
Journal of International Medical Research. 1977;5:42–48. [
PubMed: 340306]
Karush RK. The use of dream analysis in the treatment of a nine-year-old obsessional boy.
Psychoanalytic Study of the Child. 1998;53:199–211. [
PubMed: 9990831]
Kasvikis Y, Marks IM. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.
Psychopharmacology. 1988;95:113–118. [
PubMed: 3133689]
Kasvikis Y, Marks IM. Clomipramine, self-exposure, and therapist-accompanied exposure in obsessive-compulsive ritualizers: two-year follow-up. Journal of Anxiety Disorders. 1988;2:291–298.
Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder.
Biological Psychiatry. 1990;28:401–414. [
PubMed: 2207219]
Kazarian SS, Evans DR. Modification of obsessional ruminations: a comparative study. Canadian Journal of Behavioural Science. 1977;9:91–100.
Kearney CA, Silverman WK. Treatment of an adolescent with obsessive-compulsive disorder by alternating response prevention and cognitive therapy: an empirical analysis.
Journal of Behavior Therapy and Experimental Psychiatry. 1990;21:39–47. [
PubMed: 2373767]
Keijsers GP, Hoogduin CA, Schaap CP. Predictors of treatment outcome in the behavioural treatment of obsessive-compulsive disorder.
British Journal of Psychiatry. 1994;165:781–786. [
PubMed: 7661936]
Keiley MK. Affect regulation and attachment focused treatment of a husband with obsessive-compulsive disorder and his wife. Journal of Couple and Relationship Therapy. 2002;1:25–44.
Kellerman J. Hypnosis as an adjunct to thought-stopping and covert reinforcement in the treatment of homicidal obsessions in a twelve-year-old boy.
International Journal of Clinical and Experimental Hypnosis. 1981;29:128–135. [
PubMed: 7275371]
Kenwright M, Marks I, Graham C, et al. Brief scheduled phone support from a clinician to enhance computer-aided self-help for obsessive-compulsive disorder: randomised controlled-trial.
Journal of Clinical Psychology. 2005;61:1499–1508. [
PubMed: 16173084]
Keuler DJ, Altemus M, Michelson D, et al. Behavioural effects of naloxone infusion in obsessive-compulsive disorder.
Biological Psychiatry. 1996;40:154–156. [
PubMed: 8793049]
Khan A, Leventhal RM, Khan S, et al. Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database.
Journal of Affective Disorders. 2002;68:183–190. [
PubMed: 12063146]
Khanna S, Gangadhar BN, Sinha V, et al. Electroconvulsive therapy in obsessive-compulsive disorder.
Convulsive Therapy. 1988;4:314–320. [
PubMed: 11940981]
Khanna S, Rajendra PN, Channabasavanna SM. Life events and onset of obsessive compulsive disorder.
International Journal of Social Psychiatry. 1988;34:305–309. [
PubMed: 3235293]
Kiloh LG, Smith JS, Johnston GF. Psychosurgery (limbic surgery), Physical Treatments in Psychiatry. Kiloh LG, Smith JS, Johnston GF, editors. Melbourne: Blackwell; 1988. pp. 277–333.
Kim CH, Chang JW, Koo MS, et al. Anterior cingulotomy for refractory obsessive-compulsive disorder.
Acta Psychiatrica Scandinavica. 2003;107:283–290. [
PubMed: 12662251]
Kim SW, Dysken MW, Kushner MG, et al. Phenomenological and pharmacological study of provoked obsessive/anxiety symptoms in obsessive-compulsive disorder: a preliminary study.
Biological Psychiatry. 1997;42:969–975. [
PubMed: 9386847]
King RA, Scahill L. The assessment and coordination of treatment of children and adolescents with OCD.
Child and Adolescent Psychiatric Clinics of North America. 1999;8:577–597. [
PubMed: 10442231]
King RA, Leonard H, March J, et al. Summary of the practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder.
Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:1110–1116. [
PubMed: 9785724]
Klassen A, Jenkinson C, Fitzpatrick R, et al. Patients' health related quality of life before and after aesthetic surgery.
British Journal of Plastic Surgery. 1996;49:433–438. [
PubMed: 8983542]
Klerman GL, Weissman MM, Rounsaville BJ, et al. Interpersonal Psychotherapy of Depression. New York: Basic Books; 1984.
Knesevich JW. Successful treatment of obsessive-compulsive disorder with clonidine hydrochloride.
American Journal of Psychiatry. 1982;139:364–365. [
PubMed: 7058953]
Knox LS, Albano AM, Barlow DH. Parental involvement in the treatment of childhood obsessive compulsive disorder: a multiple-baseline examination incorporating parents. Behavior Therapy. 1996;27:93–115.
Kobak KA, Taylor LH, Dottl SL, et al. A computer-administered telephone interview to identify mental disorders.
Journal of the American Medical Association. 1997;278:905–910. [
PubMed: 9302242]
Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.
Psychopharmacology. 1998;136:205–216. [
PubMed: 9566805]
Koran LM. Quality of life in obsessive-compulsive disorder.
Psychiatric Clinics of North America. 2000;23:509–517. [
PubMed: 10986724]
Koran LM, Cain JW, Dominguez RA, et al. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
American Journal of Psychiatry. 1996;153:1450–1454. [
PubMed: 8890679]
Koran LM, McElroy SL, Davidson JR, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Journal of Clinical Psychopharmacology. 1996;16:121–129. [
PubMed: 8690827]
Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.
American Journal of Psychiatry. 1997;154:396–401. [
PubMed: 9054789]
Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Journal of Clinical Psychiatry. 2000;61:514–517. [
PubMed: 10937610]
Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder.
European Neuropsychopharmacology. 2001;11:169–172. [
PubMed: 11313163]
Koran LM, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder.
American Journal of Psychiatry. 2002;159:88–95. [
PubMed: 11772695]
Kozak MJ, Leibowitz MR, Foa EB. Cognitive behaviour therapy and pharmacotherapy for obsessive-compulsive disorder: the NIMH-sponsored collaborative study, Obsessive-Compulsive Disorder: Contemporary Issues in Treatment. Goodman WK, Rudorfer MV, Maser JD, editors. Mahwah New Jersey: Lawrence Erlbaum Associates; 2000. pp. 501–530.
Krochmalik A, Jones MK, Menzies RG. Danger ideation reduction therapy (DIRT) for treatment-resistant compulsive washing.
Behaviour Research and Therapy. 2001;39:897–912. [
PubMed: 11480831]
Krone KP, Himle JA, Nesse RM. A standardized behavioral group treatment program for obsessive-compulsive disorder: preliminary outcomes.
Behaviour Research and Therapy. 1991;29:627–631. [
PubMed: 1759961]
Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 1999;19:172–176. [
PubMed: 10211919]
Laidlaw TM, Falloon IR, Barnfather D, et al. The stress of caring for people with obsessive compulsive disorders.
Community Mental Health Journal. 1999;35:443–450. [
PubMed: 10547119]
Laitinen LV, Singounas E. Intraoperative electrical stimulation of the brain in patients with obsessive-compulsive neurosis.
Applied Neurophysiology. 1988;51:317–323. [
PubMed: 3048212]
Lang H. Obsessive-compulsive disorders in neurosis and psychosis.
Journal of the American Academy of Psychoanalysis. 1997;25:143–150. [
PubMed: 9284026]
LaSalle VH, Cromer KR, Nelson KN, et al. Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive-compulsive disorder.
Depression and Anxiety. 2004;19:163–173. [
PubMed: 15129418]
Last CG, Strauss CC. Obsessive-compulsive disorder in childhood. Journal of Anxiety Disorders. 1989;3:295–302.
Lax T, Basoglu M, Marks IM. Expectancy and compliance as predictors of outcome in obsessive-compulsive disorder. Behavioural Psychotherapy. 1992;20:257–266.
Lecrubier Y, Sheehan D, Weiller E, et al. The MINI International Neuropsychiatric Interview (M.I.N.I.). A Short Diagnostic Structured Interview: Reliability and Validity According to the CIDI. European Psychiatry. 1997;12:224–231.
Leib PT. Integrating behavior modification and pharmacotherapy with the psychoanalytic treatment of obsessive-compulsive disorder: a case study. Psychoanalytic Inquiry. 2001;21:222–241.
Leon AC, Portera L, Weissman MM. The social costs of anxiety disorders.
British Journal of Psychiatry. 1995;166(Suppl 27):19–22. [
PubMed: 7794589]
Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison.
Archives of General Psychiatry. 1989;46:1088–1092. [
PubMed: 2686576]
Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder.
Archives of General Psychiatry. 1991;48:922–927. [
PubMed: 1929762]
Leonard HL, Lenane MC, Swedo SE, et al. Tics and Tourette's disorder: A 2- to 7-year follow-up of 54 obsessive-compulsive children.
American Journal of Psychiatry. 1992;149:1244–1251. [
PubMed: 1503140]
Leonard HL, Swedo SE, Lenane MC, et al. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents.
Archives of General Psychiatry. 1993;50:429–439. [
PubMed: 8498877]
Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents.
Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34:1460–1468. [
PubMed: 8543513]
Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41:1431–1438. [
PubMed: 12447029]
Lin HN, Chen CC. A double-blind test on the effect of bromazepam in obsessive-compulsive neurosis.
Taiwan i Hsueh Hui Tsa Chih – Journal of the Formosan Medical Association. 1979;78:267–275. [
PubMed: 35583]
Lindsay M, Crino R, Andrews G. Controlled trial of exposure and response prevention in obsessive-compulsive disorder.
British Journal of Psychiatry. 1997;171:135–139. [
PubMed: 9337948]
Lippitz B, Mindus P, Meyerson BA, et al. Obsessive compulsive disorder and the right hemisphere: topographic analysis of lesions after anterior capsulotomy performed with thermocoagulation.
Acta Neurochirurgica –Supplementum. 1997;68:61–63. [
PubMed: 9233415]
Lippitz BE, Mindus P, Meyerson BA, et al. Lesion topography and outcome after thermocapsulotomy or gamma knife capsulotomy for obsessive-compulsive disorder: relevance of the right hemisphere.
Neurosurgery. 1999;44:452–458. [
PubMed: 10069581]
Lochner C, Stein DJ. Heterogeneity of obsessive-compulsive disorder: a literature review.
Harvard Review of Psychiatry. 2003;11:113–132. [
PubMed: 12893502]
Lochner C, Mogotsi M, du Toit PL, et al. Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder.
Psychopathology. 2003;36:255–262. [
PubMed: 14571055]
Lopez-Ibor JJ Jr, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
European Neuropsychopharmacology. 1996;6:111–118. [
PubMed: 8791036]
Lovell K, Richards DA. Multiple access points and levels of entry (MAPLE): ensuring choice, accessibility and equity for CBT services. Behavioural and Cognitive Psychotherapy. 2000;28:379–392.
Lovell K, Marks IM, Noshirvani H, et al. Should treatment distinguish anxiogenic from anxiolytic obsessive-compulsive ruminations? Results of a pilot controlled study and of a clinical audit.
Psychotherapy and Psychosomatics. 1994;61:150–155. [
PubMed: 7915040]
Lovell K, Fullalove L, Garvey R, et al. Telephone treatment of obssessive-compulsive disorder. Behavioural and Cognitive Psychotherapy. 2000;28:87–91.
Lovell K, Cox D, Garvey R, et al. Agoraphobia: nurse therapist-facilitated self-help manual.
Journal of Advanced Nursing. 2003;43:623–630. [
PubMed: 12950568]
Lovell K, Ekers D, Fullford J, et al. A pilot study of a self-help manual with minimal therapist contact in the treatment of obsessive-compulsive disorder. Clinical Effectiveness in Nursing. 2005;8:122–127.
Luo F, Leckman JF, Katsovich L, et al. Prospective longitudinal study of children with tic disorders and/or obsessive-compulsive disorder: relationship of symptom exacerbations to newly acquired streptococcal infections.
Pediatrics. 2004;113:e578–e585. [
PubMed: 15173540]
McCarter RH. Directive activity and repair of the self in the cognitive behavioral treatment of obsessive compulsive disorder: a case example. Journal of Psychotherapy Integration. 1997;7:75–88.
McDougle CJ, Walsh KH. Treatment of refractory OCD, Obsessive Compulsive Disorder: A Practical Guide. Fineberg NA, Marazziti D, Stein D, editors. London: Martin Dunitz; 2001. pp. 135–152.
McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.
American Journal of Psychiatry. 1990;147:652–654. [
PubMed: 1970224]
McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy.
Journal of Clinical Psychopharmacology. 1991;11:175–184. [
PubMed: 1820757]
McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
American Journal of Psychiatry. 1993;150:647–649. [
PubMed: 8465885]
McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics.
Archives of General Psychiatry. 1994;51:302–308. [
PubMed: 8161290]
McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
American Journal of Psychiatry. 1995;152:1812–1814. [
PubMed: 8526253]
McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
Journal of Clinical Psychiatry. 1995;56:526–528. [
PubMed: 7592506]
McDougle CJ, Kresch LE, Goodman WK, et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder.
American Journal of Psychiatry. 1995;152:772–777. [
PubMed: 7726318]
McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
Archives of General Psychiatry. 2000;57:794–801. [
PubMed: 10920469]
McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.
Journal of Autism and Developmental Disorders. 2000;30:427–435. [
PubMed: 11098879]
McKay D. Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder.
Behavior Modification. 1999;23:620–629. [
PubMed: 10533443]
McKay D, Neziroglu F, Todaro JF, et al. Changes in personality disorders following behaviour therapy for obsessive-compulsive disorder. Journal of Anxiety Disorders. 1996;10:47–57.
McKay D, Todaro J, Neziroglu F, et al. Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure and response prevention.
Behaviour Research and Therapy. 1997;35:67–70. [
PubMed: 9009045]
McLean PD, Whittal ML, Thordarson DS, et al. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder.
Journal of Consulting and Clinical Psychology. 2001;69:205–214. [
PubMed: 11393598]
Magliano L, Tosini P, Guarneri M, et al. Burden on the families of patients with obsessive-compulsive disorder: a pilot study.
European Psychiatry. 1996;11:192–197. [
PubMed: 19698449]
Maina G, Albert U, Ziero S, et al. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?
International Clinical Psychopharmacology. 2003;18:23–28. [
PubMed: 12490771]
Maletzky B, McFarland B, Burt A. Refractory obsessive compulsive disorder and ECT.
Convulsive Therapy. 1994;10:34–42. [
PubMed: 8055290]
Mallery E. The Subjective Experience of OCD, A Questionnaire-Based Study from Members of the Self-Help Organisation Obsessive Action. London: Conway Hall; 1996.
Mallya GK, White K, Waternaux C, et al. Short- and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Annals of Clinical Psychiatry. 1992;4:77–80.
Mann T. Clinical Guidelines: Using Clinical Guidelines to Improve Patient Care Within the NHS. London: Department of Health; 1996.
Marazziti D, Pfanner C, Palego L, et al. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
Pharmacopsychiatry. 1997;30:245–249. [
PubMed: 9442546]
March JS. Cognitive-behavioral psychotherapy for children and adolescents with OCD: a review and recommendations for treatment.
Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34:7–18. [
PubMed: 7860461]
March JS, Mulle K. Manualized cognitive-behavioral psychotherapy for obsessive-compulsive disorder in childhood: a preliminary single case study. Journal of Anxiety Disorders. 1995;9:175–184.
March JS, Mulle K. Banishing OCD: cognitive-behavioral psychotherapy for obsessive-compulsive disorders, Psychosocial Treatments for Child and Adolescent Disorders Empirically Based Strategies for Clinical Practice. Hibbs ED, Jensen PS, editors. Washington, DC: American Psychological Association; 1996. pp. 83–102.
March JS, Mulle K. OCD in Children and Adolescents: A Cognitive-Behavioural Treatment Manual. New York: Guilford; 1998.
March JS, Johnston H, Jefferson JW, et al. Do subtle neurological impairments predict treatment resistance to clomipramine in children and adolescents with obsessive-compulsive disorder?
Journal of Child and Adolescent Psychopharmacology. 1990;1:133–140. [
PubMed: 19630661]
March JS, Mulle K, Herbel B. Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: an open trial of a new protocol-driven treatment package.
Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33:333–341. [
PubMed: 8169177]
March JS, Frances A, Carpenter D, et al. The expert consensus guideline series: treatment of obsessive-compulsive disorder.
Journal of Clinical Psychiatry. 1997;58(Suppl 4):13–72. [
PubMed: 9183300]
March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
Journal of the American Medical Association. 1998;280:1752–1756. [
PubMed: 9842950]
March JS, Franklin M, Nelson A, et al. Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder.
Journal of Clinical Child Psychology. 2001;30:8–18. [
PubMed: 11294080]
Marks I. Behaviour therapy for obsessive-compulsive disorder: a decade of progress.
Canadian Journal of Psychiatry. 1997;42:1021–1027. [
PubMed: 9469234]
Marks I, Mishan J. Dysmorphophobic avoidance with disturbed bodily perception: a pilot study of exposure therapy.
British Journal of Psychiatry. 1988;152:674–678. [
PubMed: 3167444]
Marks IM, Hodgson R, Rachman S. Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure: a two-year follow-up and issues in treatment.
British Journal of Psychiatry. 1975;127:349–364. [
PubMed: 241455]
Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals: i.
British Journal of Psychiatry. 1980;136:1–25. [
PubMed: 6986939]
Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals.
British Journal of Psychiatry. 1988;152:522–534. [
PubMed: 3167404]
Martin JL, Barbanoj MJ, Perez V, et al. Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder.
Cochrane Database Syst Rev. 2003;(3):CD003387. [
PMC free article: PMC6991466] [
PubMed: 12917964]
Mataix-Cols D, Rauch SL, Manzo PA, et al. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
American Journal of Psychiatry. 1999;156:1409–1416. [
PubMed: 10484953]
Mataix-Cols D, Marks IM, Greist JH, et al. Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial.
Psychotherapy and Psychosomatics. 2002;71:255–262. [
PubMed: 12207105]
Mataix-Cols D, Rauch SL, Baer L, et al. Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study.
American Journal of Psychiatry. 2002;159:263–268. [
PubMed: 11823269]
Matthews K, Eljamel MS. Status of neurosurgery for mental disorder in Scotland. Selective literature review and overview of current clinical activity.
British Journal of Psychiatry. 2003;182:404–411. [
PubMed: 12724243]
Mavissakalian M, Michelson L. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents?
Journal of Nervous and Mental Disease. 1983;171:301–306. [
PubMed: 6343556]
Mavissakalian M, Turner SM, Michelson L, et al. The relationship of antiobsessional and antidepressant effects of tricyclic antidepressants.
Psychopharmacology Bulletin. 1986;22:161–166. [
PubMed: 3523574]
Mawson D, Marks IM, Ramm L. Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Two year follow-up and further findings.
British Journal of Psychiatry. 1982;140:11–18. [
PubMed: 7037100]
Mehta M. A comparative study of family-based and patient-based behavioural management in obsessive-compulsive disorder.
British Journal of Psychiatry. 1990;157:133–135. [
PubMed: 2397347]
Mellman LA, Gorman JM. Successful treatment of obsessive-compulsive disorder with ECT.
American Journal of Psychiatry. 1984;141:596–597. [
PubMed: 6703146]
Mendez MF, Perryman KM, Miller BL, et al. Compulsive behaviors as presenting symptoms of frontotemporal dementia.
Journal of Geriatric Psychiatry and Neurology. 1997;10:154–157. [
PubMed: 9453681]
Metin O, Yazici K, Tot S, et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.
Human Psychopharmacology. 2003;18:463–467. [
PubMed: 12923825]
Meyer V. Modification of expectations in cases with obsessional rituals.
Behaviour Research and Therapy. 1966;4:273–280. [
PubMed: 5978682]
Milanfranchi A, Ravagli S, Lensi P, et al. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
International Clinical Psychopharmacology. 1997;12:131–136. [
PubMed: 9248868]
Mindus P, Rasmussen SA, Lindquist C. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function.
Journal of Neuropsychiatry and Clinical Neurosciences. 1994;6:467–477. [
PubMed: 7841817]
Mindus P, Edman G, Andreewitch S. A prospective, long-term study of personality traits in patients with intractable obsessional illness treated by capsulotomy.
Acta Psychiatrica Scandinavica. 1999;99:40–50. [
PubMed: 10066006]
Mitchell-Heggs N, Kelly D, Richardson A. Stereotactic limbic leucotomy: a follow-up at 16 months.
British Journal of Psychiatry. 1976;128:226–240. [
PubMed: 1252686]
Mitzman S, Duigan I. One man's group: brief cognitive-analytic group therapy and the use of sequential diagrammatic reformulation. Counselling Psychology Quarterly. 1993;6:183–192.
Mohr N, Vythilingum B, Emsley RA, et al. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
International Clinical Psychopharmacology. 2002;17:37–40. [
PubMed: 11800505]
Monteiro WO, Noshirvani HF, Marks IM, et al. Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial.
British Journal of Psychiatry. 1987;151:107–112. [
PubMed: 3315086]
Monteleone P, Catapano F, Di Martino S, et al. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment.
British Journal of Psychiatry. 1997;170:554–557. [
PubMed: 9330023]
Montgomery SA. Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharmacological Medicine. 1980;1:189–192.
Montgomery SA. Obsessive compulsive disorder is not an anxiety disorder.
International Clinical Psychopharmacology. 1993;8(Suppl 1):57–62. [
PubMed: 8254154]
Montgomery SA, Montgomery DB, Fineberg N. Early response with clomipramine in obsessive compulsive disorder: a placebo controlled study.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1990;14:719–727. [
PubMed: 2293252]
Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder.
European Neuropsychopharmacology. 1993;3:143–152. [
PubMed: 8364350]
Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.
International Clinical Psychopharmacology. 2001;16:75–86. [
PubMed: 11236072]
Montoya A, Weiss AP, Price BH, et al. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease.
Neurosurgery. 2002;50:1043–1052. [
PubMed: 11950407]
Moore KA, Burrows GD. Hypnosis in the treatment of obsessive-compulsive disorder. Australian Journal of Clinical and Experimental Hypnosis. 1991;19:63–75.
Morelli G. Adolescent compulsion: a case study involving cognitive-behavioral treatment.
Psychological Reports. 1983;53:519–522. [
PubMed: 6647699]
Moritz EK. PhD Thesis. Hofstra University; Hempstead, New York: 1998. Behavior Therapy in Game Format for the Treatment of Childhood Obsessive Compulsive Disorder.
Morphy R. An inner view of obsessional neurosis. Gestalt Journal. 1980;3:120–136.
Muller N, Putz A, Kathmann N, et al. Characteristics of obsessive-compulsive symptoms in Tourette's syndrome, obsessive-compulsive disorder, and Parkinson's disease.
Psychiatry Research. 1997;70:105–114. [
PubMed: 9194204]
Mundo E, Bellodi L, Smeraldi E. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment.
Biological Psychiatry. 1995;38:525–531. [
PubMed: 8562664]
Mundo E, Bareggi SR, Pirola R, et al. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
Journal of Clinical Psychopharmacology. 1997;17:4–10. [
PubMed: 9004050]
Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Journal of Clinical Psychopharmacology. 1997;17:267–271. [
PubMed: 9241005]
Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
International Clinical Psychopharmacology. 1998;13:219–224. [
PubMed: 9817627]
Mundo E, Bareggi SR, Pirola R, et al. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?
Biological Psychiatry. 1999;45:290–294. [
PubMed: 10023504]
Mundo E, Rouillon F, Figuera ML, et al. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine.
Human Psychopharmacology. 2001;16:461–468. [
PubMed: 12404554]
Munjack DJ. The behavioral treatment of dysmorphophobia. Journal of Behavior Therapy and Experimental Psychiatry. 1978;9:53–56.
National Collaborating Centre for Mental Health.
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: Gaskell & the British Psychological Society; 2003. [
PubMed: 20704054]
National Collaborating Centre for Mental Health.
Eating Disorders: Core Interventions in the Treatment and Management of Anorexia Nervosa, Bulimia Nervosa, and Related Eating Disorders. London & Leicester: Gaskell & the British Psychological Society; 2004. [
PubMed: 23346610]
National Collaborating Centre for Mental Health. Depression: Management of Depression in Primary and Secondary Care. London & Leicester: Gaskell & the British Psychological Society; 2005.
National Collaborating Centre for Mental Health.
Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care. Leicester: British Psychological Society & the Royal College of Psychiatrists; 2005. [
PubMed: 21834190]
Nestadt G, Addington A, Samuels J, et al. The identification of OCD:related subgroups based on comorbidity.
Biological Psychiatry. 2003;53:914–920. [
PubMed: 12742679]
Nestadt G, Addington A, Samuels J, et al. The identification of OCD-related subgroups based on comorbidity: reply.
Biological Psychiatry. 2004;55:960–961. [
PubMed: 12742679]
Netten A, Curtis L. Unit Costs of Health and Social Care. Canterbury: University of Kent Personal Social Services Research Unit; 2003.
Newell R, Shrubb S. Attitude change and behaviour therapy in body dysmorphic disorder: two case reports. Behavioural and Cognitive Psychotherapy. 1994;22:163–169.
Newth S, Rachman S. The concealment of obsessions.
Behaviour Research and Therapy. 2001;39:457–464. [
PubMed: 11280343]
Neziroglu F, Khemlani-Patel S. A review of cognitive and behavioural treatment for body dysmorphic disorder.
CNS Spectrum. 2002;7:465–471. [
PubMed: 15107768]
Neziroglu F, Yaryura-Tobias JA. Body dysmorphic disorder:phenomenology and case descriptions. Behavioural Psychotherapy. 1993;21:27–36.
Neziroglu F, Yaryura-Tobias JA. Exposure, response prevention, and cognitive therapy in the treatment of body dysmorphic disorder. Behavior Therapy. 1993;24:431–438.
Neziroglu F, McKay D, Todaro J, et al. Effect of cognitive behavior therapy on persons with body dysmorphic disorder and comorbid axis II diagnoses. Behavior Therapy. 1996;27:67–77.
Neziroglu F, Yaryura-Tobias JA, Walz J, et al. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
Journal of Child and Adolescent Psychopharmacology. 2000;10:295–306. [
PubMed: 11191690]
Neziroglu F, Stevens KP, McKay D, et al. Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders.
Behaviour Research and Therapy. 2001;39:745–756. [
PubMed: 11400717]
NICE. The Guideline Development Process: Information for National Collaborating Centres and Guideline Development Groups. London: National Institute of Clinical Excellence; 2002.
NICE. Guidance on the Use of Electroconvulsive Therapy. London: NICE, Technology Appraisal; 2003. p. 59.
Nierenberg AA, Phillips KA, Petersen TJ, et al. Body dysmorphic disorder in outpatients with major depression.
Journal of Affective Disorders. 2002;69:141–148. [
PubMed: 12103460]
Noorbala AA, Hosseini SH, Mohammadi MR, et al. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder:a double-blind, placebo-controlled trial.
Journal of Clinical Pharmacy and Therapeutics. 1998;23:155–159. [
PubMed: 9786103]
Norland M. Peculiar and characteristic symptoms: a case. Homeopathy. 1988;7:190–197.
Nuttin B, Cosyns P, Demeulemeester H, et al. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder.
Lancet. 1999;354(9189):1526. [
PubMed: 10551504]
Nuttin BJ, Gabriels L, van Kuyck K, et al. Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive-compulsive disorder: anecdotal reports.
Neurosurgery Clinics of North America. 2003;14:267–274. [
PubMed: 12856493]
Nuttin BJ, Gabriels LA, Cosyns PR, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder.
Neurosurgery. 2003;52:1263–1272. [
PubMed: 12762871]
Nyman H, Andreewitch S, Lundback E, et al. Executive and cognitive functions in patients with extreme obsessive-compulsive disorder treated by capsulotomy.
Applied Neuropsychology. 2001;8:91–98. [
PubMed: 11515245]
O'Connor JJ. Why can't I get hives: brief strategic therapy with an obsessional child.
Family Process. 1983;22:201–209. [
PubMed: 6873265]
O'Connor K, Todorov C, Robillard S, et al. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study.
Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie. 1999;44:64–71. [
PubMed: 10076743]
Oliver B, Gascon J, Aparicio A, et al. Bilateral anterior capsulotomy for refractory obsessive-compulsive disorders.
Stereotactic and Functional Neurosurgery. 2003;81:90–95. [
PubMed: 14742970]
Ong SB, Leng YK. The treatment of an obsessive-compulsive girl in the context of Malaysian Chinese culture.
Australian and New Zealand Journal of Psychiatry. 1979;13:255–259. [
PubMed: 293181]
Ongur D, Goff DC. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status.
Schizophrenia Research. 2005;75:349–362. [
PubMed: 15885526]
Orvin GH. Treatment of the phobic obsessive-compulsive patient with oxazepam, an improved benzodiazepine compound.
Psychosomatics. 1967;8:278–280. [
PubMed: 4862919]
O'Sullivan G, Noshirvani H, Marks I, et al. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
Journal of Clinical Psychiatry. 1991;52:150–155. [
PubMed: 2016246]
Otto M, Wilhelm S, Cohen LS, et al. Prevalence of body dysmorphic disorder in a community sample of women.
American Journal of Psychiatry. 2001;158:2061–2063. [
PubMed: 11729026]
Owens EB, Piacentini J. Case study: behavioral treatment of obsessive-compulsive disorder in a boy with comorbid disruptive behavior problems.
Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37:443–446. [
PubMed: 9549966]
Ownby RL. A cognitive behavioral intervention for compulsive handwashing with a thirteen-year-old boy. Psychology in the Schools. 1983;20:219–222.
Pallanti S, Koran LM. Intravenous, pulse loaded clomipramine in body dysmorphic disorder: two case reports. CNS Spectrum. 1996;1:54–57.
Pallanti S, Quercioli L, Paiva RS, et al. Citalopram for treatment-resistant obsessive-compulsive disorder.
European Psychiatry: The Journal of the Association of European Psychiatrists. 1999;14:101–106. [
PubMed: 10572334]
Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions.
International Journal of Neuropsychopharmacology. 2002;5:181–191. [
PubMed: 12135542]
Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Journal of Clinical Psychiatry. 2002;63:796–801. [
PubMed: 12363120]
Parfitt A. Notes on some technical problems in a case of obsessional neurosis. Journal of Child Psychotherapy. 1999;25:115–139.
Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
American Journal of Psychiatry. 1988;145:1521–1525. [
PubMed: 3057923]
Pato MT, Pigott TA, Hill JL, et al. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder.
American Journal of Psychiatry. 1991;148:127–129. [
PubMed: 1984696]
Pauls DL, Alsobrook JP, Goodman W, et al. A family study of obsessive-compulsive disorder.
American Journal of Psychiatry. 1995;152:76–84. [
PubMed: 7802125]
Pelton CL. Born obsessing. Psychotherapy Patient. 1987;3:131–142.
Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood.
Lancet. 1999;354(9185):1153–1158. [
PubMed: 10513708]
Perse TL, Greist JH, Jefferson JW, et al. Fluvoxamine treatment of obsessive-compulsive disorder.
American Journal of Psychiatry. 1987;144:1543–1548. [
PubMed: 3120604]
Perugi G, Giannotti D, Di Vaio S, et al. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia).
International Clinical Psychopharmacology. 1996;11:247–254. [
PubMed: 9031991]
Peter H, Tabrizian S, Hand I. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.
International Journal of Psychiatry in Medicine. 2000;30:27–39. [
PubMed: 10900559]
Philippopulis GS. The analysis of a case of dysmorphophobia.
Canadian Journal of Psychiatry. 1979;24:397–401. [
PubMed: 487333]
Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness.
American Journal of Psychiatry. 1991;148:1138–1149. [
PubMed: 1882990]
Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder.
Psychopharmacology Bulletin. 1996;32:175–180. [
PubMed: 8927669]
Phillips KA. Pharmacologic treatment of body dysmorphic disorder.
Psychopharmacology Bulletin. 1996;32:597–605. [
PubMed: 8993080]
Phillips KA. Quality of life for patients with body dysmorphic disorder.
Journal of Nervous and Mental Disease. 2000;188:170–175. [
PubMed: 10749282]
Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach.
CNS Spectrum. 2002;7:453–460. [
PubMed: 15107767]
Phillips KA, Diaz SF. Gender differences in body dysmorphic disorder.
Journal of Nervous and Mental Disease. 1997;185:570–577. [
PubMed: 9307619]
Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder.
Journal of Clinical Psychiatry. 2003;64:715–720. [
PubMed: 12823088]
Phillips KA, McElroy SL, Keck PE Jr, et al. Body dysmorphic disorder: 30 cases of imagined ugliness.
American Journal of Psychiatry. 1993;150:302–308. [
PubMed: 8422082]
Phillips KA, Kim JM, Hudson JI. Body image disturbance in body dysmorphic disorder and eating disorders. Obsessions or delusions?
Psychiatric Clinics of North America. 1995;18:317–334. [
PubMed: 7659601]
Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvox-amine in body dysmorphic disorder.
Journal of Clinical Psychiatry. 1998;59:165–171. [
PubMed: 9590666]
Phillips KA, Dufresne RG Jr, Wilkel CS, et al. Rate of body dysmorphic disorder in dermatology patients.
Journal of the Americal Academy of Dermatology. 2000;42:436–441. [
PubMed: 10688713]
Phillips KA, Albertini RS, Siniscalchi JM, et al. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
Journal of Clinical Psychiatry. 2001;62:721–727. [
PubMed: 11681769]
Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
Archives of General Psychiatry. 2002;59:381–388. [
PubMed: 11926939]
Piacentini J. Cognitive behavioral therapy of childhood OCD.
Child and Adolescent Psychiatric Clinics of North America. 1999;8:599–616. [
PubMed: 10442232]
Piacentini J, Gitow A, Jaffer M, et al. Outpatient behavioral treatment of child and adolescent obsessive compulsive disorder. Journal of Anxiety Disorders. 1994;8:277–289.
Piacentini J, Bergman RL, Jacobs C, et al. Open trial of cognitive behavior therapy for childhood obsessive-compulsive disorder.
Journal of Anxiety Disorders. 2002;16:207–219. [
PubMed: 12194545]
Pidrman V, Tuma I. Fenfluramine challenge test in obsessive-compulsive disorder: first results.
Acta Medica (Hradec Kralove). 1997;40:99–102. [
PubMed: 9481883]
Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results.
Archives of General Psychiatry. 1990;47:926–932. [
PubMed: 2222131]
Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 1991;11:242–248. [
PubMed: 1918422]
Pigott TA, L'Heureux F, Rubenstein CS, et al. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 1992;12:156–162. [
PubMed: 1629380]
Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 1992;12:11–18. [
PubMed: 1552034]
Pigott TA, L'Heureux F, Rubenstein CF, et al. A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. New Research Abstracts NR144 presented at the 145th Annual Meeting of the American Psychiatric Association; Washington, DC: USA. 1992.
Pitman RK, Green RC, Jenike MA, et al. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder.
American Journal of Psychiatry. 1987;144:1166–1171. [
PubMed: 3477103]
Pollard JW. Don't go there: impulse control in stage-specific short term counselling. Journal of College Student Psychotherapy. 2001;16:65–84.
POTS. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
Journal of the American Medical Association. 2004;292:1969–1976. [
PubMed: 15507582]
Prasad A. A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis.
Pharmacopsychiatry. 1984;17:61–62. [
PubMed: 6233622]
Price LH, Goodman WK, Charney DS, et al. Treatment of severe obsessive-compulsive disorder with fluvoxamine.
American Journal of Psychiatry. 1987;144:1059–1061. [
PubMed: 3111279]
Querioz LOS, Motta MA, Madi MBBP, et al. A functional analysis of obsessive-compulsive problems with related therapeutic procedures.
Behaviour Research and Therapy. 1981;19:377–388. [
PubMed: 7316914]
Rabavilas AD, Boulougouris JC, Perissaki C. Therapist qualities related to outcome with exposure in vivo in neurotic patients. Journal of Behavior Therapy and Experimental Psychiatry. 1979;10:293–294.
Rachman S. Pollution of the mind.
Behaviour Research and Therapy. 1994;32:311–314. [
PubMed: 8192629]
Rachman S. A cognitive theory of obsessions.
Behaviour Research and Therapy. 1997;35:793–802. [
PubMed: 9299799]
Rachman S. A cognitive theory of obsessions: elaborations.
Behaviour Research and Therapy. 1998;36:385–401. [
PubMed: 9670600]
Rachman S. A cognitive theory of compulsive checking.
Behaviour Research and Therapy. 2002;40:624–639. [
PubMed: 12051482]
Rachman SJ. The Treatment of Obsessions. Oxford: Oxford University Press; 2003.
Rachman S. Fear of contamination.
Behaviour Research and Therapy. 2004;42:1227–1255. [
PubMed: 15381436]
Rachman SJ, de Silva P. Abnormal and normal obsessions.
Behaviour Research and Therapy. 1978;16:233–238. [
PubMed: 718588]
Rachman S, Hodgson R, Marks IM. The treatment of chronic obsessive-compulsive neurosis.
Behaviour Research and Therapy. 1971;9:237–247. [
PubMed: 5095079]
Rachman S, Marks IM, Hodgson R. The treatment of obsessive-compulsive neurotics by modelling and flooding in vivo.
Behaviour Research and Therapy. 1973;11:463–471. [
PubMed: 4777642]
Rao S. Fluoxetine was safe and effective for body dysmorphic disorder.
Evidence-Based Mental Health. 2002;5:119. [
PubMed: 12440460]
Raphael FJ, Rani S, Bale R, et al. Religion, ethnicity and obsessive-compulsive disorder.
International Journal of Social Psychiatry. 1996;42:38–44. [
PubMed: 8730535]
Rapoport JL, Inoff-Germain G. Treatment of obsessive-compulsive disorder in children and adolescents.
Journal of Child Psychology and Psychiatry. 2000;41:419–431. [
PubMed: 10836672]
Rapoport J, Elkins R, Mikkelsen E. Clinical controlled trial of chlorimipramine in adolescents with obsessive-compulsive disorder.
Psychopharmacology Bulletin. 1980;16:61–63. [
PubMed: 6996027]
Rapoport JL, Leonard HL, Swedo SE, et al. Obsessive compulsive disorder in children and adolescents: issues in management.
Journal of Clinical Psychiatry. 1993;54(Suppl 6):27–29. [
PubMed: 8331099]
Rasmussen SA, Eisen JL. Epidemiology and clinical features of obsessive compulsive disorder, Obsessive Compulsive Disorders: Theory and Management. Jenike MA, Bae L, Minichiello WE, editors. Chicago: Year Book Medical; 1990. pp. 10–27.
Rasmussen SA, Eisen JL. Epidemiology of obsessive compulsive disorder.
Journal of Clinical Psychiatry. 1990;51(Suppl):10–13. [
PubMed: 2404965]
Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder.
Journal of Clinical Psychiatry. 1994;55:5–14. [
PubMed: 7961532]
Rasmussen S, Greenberg B, Mindus P, et al. Neurosurgical approaches to intractable obsessive-compulsive disorder.
CNS Spectrum. 2000;5:23–34. [
PubMed: 18188146]
Ravizza L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder.
Journal of Clinical Psychiatry. 1995;56:368–373. [
PubMed: 7635854]
Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Psychopharmacology Bulletin. 1996;32:167–173. [
PubMed: 8927668]
Reichenberg UJ, Ullman R. A violent child with an attitude. Townsend Letter. 1998;178:52.
Reichenberg UJ, Ullman R. A grieving mother with obsessive-compulsive tendencies. Townsend Letter. 1998;177:38–39.
Reichenberg UJ, Ullman R. Everything in its place: the torment of obsessive-compulsive disorder. Townsend Letter. 1999;195:132–135.
Reichenberg UJ, Ullman R. The fascinating and debilitating world of OCD. Journal of the American Institute of Homeopathy. 2000;93:132–139.
Rettew DC, Swedo SE, Leonard HL, et al. Obsessions and compulsions across time in 79 children and adolescents with obsessive-compulsive disorder.
Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31:1050–1056. [
PubMed: 1429404]
Rheaume J, Freeston M, Leger E, et al. Bad luck: an underestimated factor in the development of obsessive-compulsive disorder. Clinical Psychology and Psychotherapy. 1998;5:1–12.
Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31:1062–1069. [
PubMed: 1429406]
Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:222–229. [
PubMed: 11211371]
Riding J, Munro A. Pimozide in the treatment of monosymptomatic hypochondriacal psychosis.
Acta Psychiatrica Scandinavica. 1975;52:23–30. [
PubMed: 1155199]
Robins LN, Holzer JE, Weissman MM. Lifetime prevalence of psychiatric disorders in three sites.
Archives of General Psychiatry. 1984;41:949–958. [
PubMed: 6332590]
Romano S, Goodman W, Tamura R, et al. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.
Journal of Clinical Psychopharmacology. 2001;21:46–52. [
PubMed: 11199947]
Rosen JC, Saltzberg E, Srebnik D. Cognitive behavior therapy for negative body image. Behavior Therapy. 1989;20:393–404.
Rosen JC, Reiter J, Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder.
Journal of Consulting and Clinical Psychology. 1995;63:263–269. [
PubMed: 7751487]
Rosenfeld R, Dar R, Anderson D, et al. A computer-administered version of the Yale-Brown Obsessive Compulsive Scale. Psychological Assessment. 1992;4:329–332.
Rosqvist J, Egan D, Manzo P, et al. Home-based behavior therapy for obsessive-compulsive disorder: a case series with data.
Journal of Anxiety Disorders. 2001;15:395–400. [
PubMed: 11583072]
Rosso SM, Roks G, Stevens M, et al. Complex compulsive behaviour in the temporal variant of frontotemporal dementia.
Journal of Neurology. 2001;248:965–970. [
PubMed: 11757960]
Roth A, Fonagy P. What Works for Whom? A Critical Review of Psychotherapy Research. 2nd ed. London: Guilford; 2004.
Rothbaum BO, Fran S. Behavioural treatment of obsessive-compulsive disorder in a naturalistic setting. Cognitive and Behavioural Practice. 2000;7:262–270.
Sachdev P. Site and size of lesion and psychosurgical outcome in obsessive-compulsive disorder: a magnetic resonance imaging study.
Biological Psychiatry. 1996;39:739–742. [
PubMed: 8731462]
Sachdev P, Hay P. Does neurosurgery for obsessive-compulsive disorder produce personality change?
Journal of Nervous and Mental Disease. 1995;183:408–413. [
PubMed: 7798091]
Sachdev PS, McBride R, Loo CK, et al. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation.
Journal of Clinical Psychiatry. 2001;62:981–984. [
PubMed: 11780880]
Salkovskis PM. Obsessive-compulsive problems: a cognitive behavioural analysis.
Behaviour Research and Therapy. 1985;23:571–583. [
PubMed: 4051930]
Salkovskis PM. Understanding and treating obsessive-compulsive disorder.
Behaviour Research and Therapy. 1999;37(Suppl 1):S29–S52. [
PubMed: 10402695]
Salkovskis PM, Warwick HM. Cognitive therapy of obsessive-compulsive disorder: treating treatment failures. Behavioural Psychotherapy. 1986;13:243–255.
Salkovskis PM, Richards CH, Forrester E. The relationship between obsessional problems and intrusive thoughts. Behavioural and Cognitive Psychotherapy. 1995;23:281–299.
Salkovskis PM, Shafran R, Rachman S, et al. Multiple pathways to inflated responsibility beliefs in obsessional problems: possible origins and implications for therapy and research.
Behaviour Research and Therapy. 1999;37:1055–1072. [
PubMed: 10500320]
Salkovskis PM, Thorpe SJ, Wahl K, et al. Neutralizing increases discomfort associated with obsessional thoughts: an experimental study with obsessional patients.
Journal of Abnormal Psychology. 2003;112:709–715. [
PubMed: 14674881]
Sallee FR, Koran LM, Pallanti S, et al. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks.
Biological Psychiatry. 1998;44:220–227. [
PubMed: 9693393]
Salzberg AD, Swedo SE. Oxytocin and vasopressin in obsessive-compulsive disorder.
American Journal of Psychiatry. 1992;149:713–714. [
PubMed: 1575271]
Salzman L. Psychoanalytic therapy of the obsessional patient.
Current Psychiatric Therapies. 1983;22:53–59. [
PubMed: 6677441]
Salzman L. Therapy of the obsessive personality, Essential Papers in Psychoanalysis, Essential Papers on Obsessive-Compulsive Disorder. Stein DJ, Stone MH, editors. New York: New York University Press; 1997. pp. 124–160.
Sarwer DB, Wadden TA, Pertschuk MJ, et al. Body image dissatisfaction and body dysmorphic disorder in 100 cosmetic surgery patients.
Plastic and Reconstructive Surgery. 1998;101:1644–1649. [
PubMed: 9583501]
Saxena S, Brody AL, Schwartz JM, et al. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder.
British Journal of Psychiatry. 1998;173(Suppl 35):26–37. [
PubMed: 9829024]
Scahill L, Vitulano LA, Brenner EM, et al. Behavioral therapy in children and adolescents with obsessive-compulsive disorder: a pilot study.
Journal of Child and Adolescent Psychopharmacology. 1996;6:191–202. [
PubMed: 9231312]
Scahill L, Riddle MA, McSwiggin HM, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity.
Journal of the American Academy of Child and Adolescent Psychiatry. 1997;36:844–852. [
PubMed: 9183141]
Schmidt NB, Harrington P. Cognitive-behavioral treatment of body dysmorphic disorder: a case report.
Journal of Behavior Therapy and Experimental Psychiatry. 1995;26:161–167. [
PubMed: 7593690]
Schwartz EK. The treatment of the obsessive patient in the group therapy setting.
American Journal of Psychotherapy. 1972;26:352–361. [
PubMed: 5037774]
Schwartz JM, Stoessel PW, Baxter L Jr, et al. Systematic changes in cerebral glucose metabolic rate after successful behaviour modification treatment of obsessive-compulsive disorder.
Archives of General Psychiatry. 1996;53:109–113. [
PubMed: 8629886]
Scrignar CB. Rapid treatment of contamination phobia with hand-washing compulsion by flooding with hypnosis.
American Journal of Clinical Hypnosis. 1981;23:252–257. [
PubMed: 7282577]
Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 2003;23:448–450. [
PubMed: 14520120]
Shafran R. The manipulation of responsibility in obsessive-compulsive disorder.
British Journal of Clinical Psychology. 1997;36(Pt 3):397–407. [
PubMed: 9309355]
Shafran R, Ralph J, Tallis F. Obsessive-compulsive symptoms and the family.
Bulletin of the Menninger Clinic. 1995;59:472–479. [
PubMed: 8535386]
Shafran R, Frampton I, Heyman I, et al. The preliminary development of a new self-report measure for OCD in young people.
Journal of Adolescence. 2003;26:137–142. [
PubMed: 12550826]
Shannahoff-Khalsa DS, Ray LE, Levine S, et al. Randomized controlled trial of yogic meditation techniques for patients with obsessive-compulsive disorder.
CNS Spectrum. 1999;4:34–47. [
PubMed: 18311106]
Shaomei L, Numerous C. Combination of clomipramine with exposure therapy in treatment of obsessive-compulsive disorder. Chinese Mental Health Journal. 2000;15:239–240. Chinese.
Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
Biological Psychiatry. 2004;55:553–555. [
PubMed: 15023585]
Shapiro DA, Cavanagh K, Lomas H. Geographic inequity in the availability of cognitive behavioural therapy in England and Wales.
Behavioural and Cognitive Psychotherapy. 2003;31:185–192. [
PubMed: 23829940]
Sheinberg M. Obsessions/counter-obsessions: a construction/reconstruction of meaning.
Family Process. 1988;27:305–316. [
PubMed: 3224701]
Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.
Depression and Anxiety. 2004;19:225–233. [
PubMed: 15274171]
Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder.
Archives of General Psychiatry. 1999;56:121–127. [
PubMed: 10025435]
Slattery MJ, Dubbert BK, Allen AJ, et al. Prevalence of obsessive-compulsive disorder in patients with systemic lupus erythematosus.
Journal of Clinical Psychiatry. 2004;65:301–306. [
PubMed: 15096067]
Smeraldi E, Erzegovesi S, Bianchi I, et al. Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends in Experimental and Clinical Psychiatry. 1992;8:63–65.
Sobanski E, Schmidt MH. ‘Everybody looks at my pubic bone’: a case report of an adolescent patient with body dysmorphic disorder.
Acta Psychiatrica Scandinavica. 2000;101:80–82. [
PubMed: 10674954]
Solyom L, DiNicola VF, Phil M, et al. Is there an obsessive psychosis? Aetiological and prognostic factors of an atypical form of obsessive-compulsive neurosis.
Canadian Journal of Psychiatry. 1985;30:372–379. [
PubMed: 4027863]
Sondheimer A. Clomipramine treatment of delusional disorder-somatic type.
Journal of the American Academy of Child and Adolescent Psychiatry. 1988;27:188–192. [
PubMed: 3360722]
Soomro GM. Sertraline reduced patient dropout rates and acute exacerbation of symptoms in obsessive compulsive disorder.
Evidence-Based Mental Health. 2002;5:115. [
PubMed: 12440456]
Spangler WJ, Cosgrove GR, Ballantine HT Jr, et al. Magnetic resonance image-guided stereotactic cingulotomy for intractable psychiatric disease.
Neurosurgery. 1996;38:1071–1076. [
PubMed: 8727135]
Stanley L. Treatment of ritualistic behaviour in an eight-year-old girl by response prevention: a case report.
Journal of Child Psychology and Psychiatry and Allied Disciplines. 1980;21:85–90. [
PubMed: 7358808]
Stanley MA, Turner SM. Current status of pharmacological and behaviour treatment of obsessive-compulsive disorder. Behaviour Therapy. 1995;26:163–168.
Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorders.
Biological Psychiatry. 2000;47:296–304. [
PubMed: 10686264]
Stein DJ. Obsessive-compulsive disorder.
Lancet. 2002;360:397–405. [
PubMed: 12241794]
Stein DJ, Hollander E, Mullen LS, et al. Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder. Human Psychopharmacology. 1992;7:389–395.
Stein DJ, Laszlo B, Marais E, et al. Hoarding symptoms in patients on a geriatric psychiatry inpatient unit.
South African Medical Journal. 1997;87:1138–1140. [
PubMed: 9358832]
Stein DJ, Van Heerden B, Wessels CJ, et al. Single photon emission computed tomography of the brain with Tc-99 m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: Investigating the functional role of the serotonin auto-receptor.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1999;23:1079–1099. [
PubMed: 10621951]
Stein DJ, Montgomery SA, Kasper S, et al. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.
International Clinical Psychopharmacology. 2001;16:357–361. [
PubMed: 11712625]
Stein MB, Forde DR, Anderson G, et al. Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal.
American Journal of Psychiatry. 1997;154:1120–1126. [
PubMed: 9247399]
Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders.
American Journal of Psychiatry. 2004;161:2230–2237. [
PubMed: 15569894]
Steketee G. Treatment of Obsessive Compulsive Disorder. New York: Guilford Press; 1993.
Steketee G. Behavioural assessment and treatment planning with obsessive compulsive disorder: a review emphasizing clinical application. Behavior Therapy. 1994;25:613–633.
Steketee G, Frost R. Compulsive hoarding: current status of the research.
Clinical Psychology Reviews. 2003;23:905–927. [
PubMed: 14624821]
Steketee G, Foa EB, Grayson JB. Recent advances in the behavioral treatment of obsessive-compulsives.
Archives of General Psychiatry. 1982;39:1365–1371. [
PubMed: 7149895]
Steketee G, Frost R, Bogart K. The Yale-Brown Obsessive Compulsive Scale: interview versus self-report.
Behaviour Research and Therapy. 1996;34:675–684. [
PubMed: 8870295]
Stengler-Wenzke K, Trosbach J, Dietrich S, et al. Experience of stigmatization by relatives of patients with obsessive compulsive disorder.
Archives of Psychiatric Nursing. 2004;18:88–96. [
PubMed: 15199536]
Stern RS. Contract therapy in obsessive-compulsive neurosis with marital discord.
British Journal of Psychiatry. 1973;123:681–684. [
PubMed: 4772311]
Stern RS, Lipsedge MS, Marks IM. Obsessive ruminations: a controlled trial of thought-stopping technique.
Behaviour Research and Therapy. 1973;11:659–662. [
PubMed: 4777659]
Stern RS, Cobb JP, Marks IM, et al. A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
Postgraduate Medical Journal. 1977;53:97–103. [
PubMed: 341110]
Stern RS, Marks IM, Wright J, et al. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.
Postgraduate Medical Journal. 1980;56:134–139. [
PubMed: 7393824]
Stewart SE, Geller DA, Jenike M, et al. Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature.
Acta Psychiatrica Scandinavica. 2004;110:4–13. [
PubMed: 15180774]
Strom-Olsen R, Carlisle S. Bi-frontal stereotactic tractotomy: a follow-up study of its effects on 210 patients.
British Journal of Psychiatry. 1971;118:141–154. [
PubMed: 4930549]
Swedo SE, Rapoport JL, Leonard HL, et al. Obsessive-compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases.
Archives of General Psychiatry. 1989;46:335–341. [
PubMed: 2930330]
Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases.
American Journal of Psychiatry. 1998;155:264–271. [
PubMed: 9464208]
Szegedi A, Wetzel H, Leal M, et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Journal of Clinical Psychiatry. 1996;57:257–264. [
PubMed: 8666564]
Tass PA, Klosterkotter J, Schneider F, et al. Obsessive-compulsive disorder: development of demand-controlled deep brain stimulation with methods from stochastic phase resetting.
Neuropsychopharmacology. 2003;28(Suppl 1):S27–S34. [
PubMed: 12827141]
Taylor LH, Kobak KA. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder.
Journal of Clinical Psychiatry. 2000;61:575–578. [
PubMed: 10982200]
Taylor RE. Imagery for the treatment of obsessional behavior: a case study.
American Journal of Clinical Hypnosis. 1985;27:175–179. [
PubMed: 3976549]
Taylor S. Assessment of obsessions and compulsions: reliability, validity, and sensitivity to treatment effects. Clinical Psychology Reviews. 1995;15:261–296.
Taylor S, Thordarson DS, Sachting I. Obsessive-compulsive disorder, Handbook of Assessment and Treatment Planning for Psychological Disorders. Anthony MM, Barlow DH, editors. New York: Guilford Press; 2002. pp. 182–214.
Taylor S, Thordarson DS, Spring T, et al. Telephone-administered cognitive behavior therapy for obsessive-compulsive disorder.
Cognitive Behaviour Therapy. 2003;32:13–25. [
PubMed: 16291531]
Tek C, Ulug B. Religiosity and religious obsessions in obsessive-compulsive disorder.
Psychiatry Research. 2001;104:99–108. [
PubMed: 11711164]
Tenney NH, Denys DA, van Megen HJ, et al. Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder.
International Clinical Psychopharmacology. 2003;18:29–33. [
PubMed: 12490772]
Thienemann M, Martin J, Cregger B, et al. Manual-driven group cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: a pilot study.
Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:1254–1260. [
PubMed: 11699798]
Thomas SG, Kellner CH. Remission of major depression and obsessive-compulsive disorder after a single unilateral ECT.
Journal of ECT. 2003;19:50–51. [
PubMed: 12621279]
Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.
Archives of General Psychiatry. 1980;37:1281–1285. [
PubMed: 7436690]
Tippin J, Henn FA. Modified leukotomy in the treatment of intractable obsessional neurosis.
American Journal of Psychiatry. 1982;139:1601–1603. [
PubMed: 7149061]
Tolin DF. Case study: bibliotherapy and extinction treatment of obsessive-compulsive disorder in a 5-year-old boy.
Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40:1111–1114. [
PubMed: 11556636]
Tolin DF, Franklin ME. Prospects for the use of cognitive-behavioral therapy in childhood obsessive-compulsive disorder.
Expert Review of Neurotherapeutics. 2002;2:539–548. [
PubMed: 19810951]
Tollefson GD, Birkett M, Koran L, et al. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Journal of Clinical Psychiatry. 1994;55:69–76. [
PubMed: 7961535]
Turgeon L, O'Connor KP, Marchand A, et al. Recollections of parent-child relationships in patients with obsessive-compulsive disorder and panic disorder with agoraphobia.
Acta Psychiatrica Scandinavica. 2002;105:310–316. [
PubMed: 11942936]
Turner SM, Jacob RG, Beidel DC, et al. Fluoxetine treatment of obsessive-compulsive disorder.
Journal of Clinical Psychopharmacology. 1985;5:207–212. [
PubMed: 3894437]
Ushijima S, Kamijima K, Asai M, et al. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: a double blind placebo controlled trial. Japanese Journal of Neuropsychopharmacology. 1997;19:603–623. Japanese.
Uzun O, Basoglu C, Akar A, et al. Body dysmorphic disorder in patients with acne.
Comprehensive Psychiatry. 2003;44:415–419. [
PubMed: 14505303]
Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.
British Journal of Psychiatry. 1992;161:665–670. [
PubMed: 1422616]
Valleni-Basile LA, Garrison CZ, Jackson KL, et al. Frequency of obsessive-compulsive disorder in a community sample of young adolescents.
Journal of the American Academy of Child and Adolescent Psychiatry. 1994;33:782–791. [
PubMed: 8083134]
Van Balkom AJLM, van Oppen P, Vermeulen AWA, et al. A meta-analysis on the treatment of obsessive compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy. Clinical Psychology Review. 1994;14:359–381.
Van Balkom AJ, de Haan E, van Oppen P, et al. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder.
Journal of Nervous and Mental Disease. 1998;186:492–499. [
PubMed: 9717867]
Van Noppen B, Steketee G, McCorkle BH, et al. Group and multifamily behavioral treatment for obsessive compulsive disorder: a pilot study.
Journal of Anxiety Disorders. 1997;11:431–446. [
PubMed: 9276786]
Van Noppen BL, Pato MT, Marsland R, et al. A time-limited behavioral group for treatment of obsessive-compulsive disorder.
Journal of Psychotherapy Practice and Research. 1998;7:272–280. [
PMC free article: PMC3330509] [
PubMed: 9752638]
Van Oppen P, Arntz A. Cognitive therapy for obsessive-compulsive disorder.
Behaviour Research and Therapy. 1994;32:79–87. [
PubMed: 8135725]
Van Oppen P, de Haan E, van Balkom AJ, et al. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder.
Behaviour Research and Therapy. 1995;33:379–390. [
PubMed: 7755525]
Veale D. Outcome of cosmetic surgery and ‘DIY’ surgery in patients with body dysmorphic disorder. Psychiatric Bulletin. 2000;24:218–221.
Veale D. Overvalued ideas: a conceptual analysis.
Behaviour Research and Therapy. 2002;40:383–400. [
PubMed: 12002896]
Veale D. Advances in a cognitive behavioural understanding of body dysmorphic disorder.
Body Image. 2004;1:113–125. [
PubMed: 18089145]
Veale D, Boocock A, Gournay K, et al. Body dysmorphic disorder: a survey of fifty cases.
British Journal of Psychiatry. 1996;169:196–201. [
PubMed: 8871796]
Veale D, Gournay K, Dryden W, et al. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial.
Behaviour Research and Therapy. 1996;34:717–729. [
PubMed: 8936754]
Vindigni V, Pavan C, Semenzin S, et al. The importance of recognizing body dysmorphic disorder in cosmetic surgery patients: do our patients need a pre-operative psychiatric evaluation? European Journal of Plastic Surgery. 2002;25:305–308.
Vitiello B, DeLeon J. Dysmorphophobia misdiagnosed as obsessive-compulsive disorder.
Psychosomatics. 1990;31:220–222. [
PubMed: 2330405]
Vogel PA, Stiles TC, Nordahl HM. Recollections of parent-child relationships in OCD out-patients compared to depressed out-patients and healthy controls.
Acta Psychiatrica Scandinavica. 1997;96:469–474. [
PubMed: 9421344]
Vogel PA, Stiles TC, Gotestam G. Adding cognitive therapy elements to exposure therapy for obsessive compulsive disorder: a controlled study. Behavioural and Cognitive Psychotherapy. 2004;32:275–290.
Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder.
Psychiatry Research. 1985;14:85–93. [
PubMed: 3887445]
Walker WL. The secret room for problem solving. Australian Journal of Clinical and Experimental Hypnosis. 1981;9:102–103.
Warneke LB. Intravenous chlorimipramine in the treatment of obsessional disorder in adolescence: case report.
Journal of Clinical Psychiatry. 1985;46:100–103. [
PubMed: 3972776]
Waters TL, Barrett PM, March JS. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: preliminary findings.
American Journal of Psychotherapy. 2001;55:372–387. [
PubMed: 11641879]
Watts FN. Aversion to personal body hair: a case study in the integration of behavioural and interpretative methods.
British Journal of Medical Psychology. 1990;63:335–340. [
PubMed: 2081157]
Waxman D. A clinical trial of clomipramine and diazepam in the treatment of phobic and obsessional illness.
Journal of International Medical Research. 1977;5:99–110. [
PubMed: 598611]
Waziri R. Psychosurgery for anxiety and obsessive-compulsive disorders, The Treatment of Anxiety: Handbook of Anxiety. Noyes R, Roth M, Burrows GD, editors. Amsterdam: Elsevier; 1990.
Weiner IB. Behaviour therapy in obsessive-compulsive neurosis treatment of an adolescent boy. Psychotherapy: Theory, Research and Practice. 1967;4:27–29.
Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Journal of Clinical Psychiatry. 1999;60:524–527. [
PubMed: 10485634]
Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group.
Journal of Clinical Psychiatry. 1994;55(Suppl):5–10. [
PubMed: 8077177]
Weissman MM, Broadhead WE, Olfson M, et al. A diagnostic aid for detecting (DSM-IV) mental disorders in primary care.
General Hospital Psychiatry. 1998;20:1–11. [
PubMed: 9506249]
Welkowitz LA, Struening EL, Pittman J, et al. Obsessive-compulsive disorder and comorbid anxiety problems in a national anxiety screening sample.
Journal of Anxiety Disorders. 2000;14:471–482. [
PubMed: 11095541]
Wells A. Emotional Disorders and Metacognition: Innovative Cognitive Therapy. New York, NY: John Wiley & Sons; 2000.
Wells MC. Treating obsessive-compulsive personalities in psychodynamic/ interpersonal group therapy. Psychotherapy: Theory, Research, Practice, Training. 1990;27:366–379.
Wever C, Rey JM. Juvenile obsessive-compulsive disorder.
Australian and New Zealand Journal of Family Therapy. 1997;31:105–113. [
PubMed: 9088493]
Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder.
Psychiatry Research. 2004;132:69–79. [
PubMed: 15546704]
Whittal ML, Thordarson DS, McLean PD. Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs. exposure and response prevention.
Behaviour Research and Therapy. 2005;43:1559–1576. [
PubMed: 15913543]
Wilhelm S, Otto MW, Zucker BG, et al. Prevalence of body dysmorphic disorder in patients with anxiety disorders.
Journal of Anxiety Disorders. 1997;11:499–502. [
PubMed: 9407269]
Wilhelm S, Otto MW, Lohr B, et al. Cognitive behavior group therapy for body dysmorphic disorder: a case series.
Behaviour Research and Therapy. 1999;37:71–75. [
PubMed: 9922559]
Williams TI, Allsopp M. Obsessional compulsive disorder in adolescent populations: experiences of offering a combined pharmacological-psychological approach. Child Psychology and Psychiatry Review. 1999;4:162–169.
Williams TI, Salkovskis PM, Forrester EA, et al. Changes in symptoms of OCD and appraisal of responsibility during cognitive behavioural treatment: a pilot study. Behavioural and Cognitive Psychotherapy. 2002;30:69–78.
Willick MS. Obsessive-compulsive disorder? Or, a narcissistic solution in an obsessional man? A nineteen-year treatment in progress. Journal of Clinical Psychoanalysis. 1995;4:149–168.
Willmuth ME. Cognitive-behavioral and insight-oriented psychotherapy of an eleven-year-old boy with obsessive-compulsive disorder.
American Journal of Psychotherapy. 1988;42:472–478. [
PubMed: 3177711]
Wolff R, Rapoport J. Behavioral treatment of childhood obsessive-compulsive disorder.
Behavior Modification. 1998;12:252–266. [
PubMed: 3069095]
Wolff RP, Wolff LS. Assessment and treatment of obsessive-compulsive disorder in children.
Behavior Modification. 1991;15:372–393. [
PubMed: 1953625]
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
Yamagami T. Changes of behavior, fear and thought in the treatment by response prevention: a case study of obsessive compulsive disorder.
Folia Psychiatrica et Neurologica Japonica. 1978;32:77–83. [
PubMed: 658852]
Yargic LI, Enderer M, Imre H, et al. A randomized single blind comparison of clomipramine and fluvoxamine in OCD patients. Noropsikiyatri Arsivi. 1995;32:70–75. Turkish.
Yaryura-Tobias JA, Bhagavan HN. L-tryptophan in obsessive-compulsive disorders.
American Journal of Psychiatry. 1977;134:1298–1299. [
PubMed: 333953]
Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder.
Archives of General Psychiatry. 1996;53:653–654. [
PubMed: 8660133]
Yaryura-Tobias JA, Neziroglu F, Bergman L. Chlorimipramine, for obsessive-compulsive neurosis: an organic approach.
Current Therapeutic Research. 1976;20:541–548. [
PubMed: 806424]
Yoder J. Paradoxical intention: the case of Ron. International Forum for Logotherapy. 1994;17:108–113.
Zahn TP, Insel TR, Murphy DL. Psychophysiological changes during pharmacological treatment of patients with obsessive compulsive disorder.
British Journal of Psychiatry. 1984;145:39–44. [
PubMed: 6378303]
Zhang PG, Zhong Q, Yu YE. Controlled observation on electro-acupuncture combined with clomipramine in treating obsession.
Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi. 2002;22:215–216. Chinese. [
PubMed: 12585112]
Zikis P. Treatment of an 11 year old obsessive compulsive ritualizer and tiquear girl with in vivo exposure and response prevention. Behavioural Psychotherapy. 1983;11:75–81.
Zimmerman M, Mattia JI. Body dysmorphic disorder in psychiatric outpatients: recognition, prevalence, comorbidity, demographic, and clinical correlates.
Comprehensive Psychiatry. 1998;39:265–270. [
PubMed: 9777278]
Zitterl W, Meszaros K, Hornik K, et al. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
Wiener Klinische Wochenschrift. 1999;111:439–442. [
PubMed: 10420495]
Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Biological Psychiatry. 1987;22:667–687. [
PubMed: 3036259]
Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
British Journal of Psychiatry. 1996;169:468–474. [
PubMed: 8894198]
Zohar J, Mueller EA, Insel TR, et al. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls.
Archives of General Psychiatry. 1987;44:946–951. [
PubMed: 3675134]
